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The reduction-oxidation (redox) reaction involves a change in the oxidation state of 
molecules where a molecule that donates an electron is oxidized and a molecule that 
accepts an electron is reduced. The NADPH oxidase of myeloid cells, NOX2, is a 
major source of oxidants in the form of reactive oxygen species (ROS), which are short-
lived oxygen derivatives. NOX2-derived ROS have been ascribed a pivotal role in the 
elimination of pathogens and may be toxic also to host cells and tissues. ROS may also act 
as signaling molecules and thus regulate biological processes such as cell cycle proliferation, 
differentiation, cell death, blood vessel formation, and immunity. The purpose of this thesis 
was to contribute to the understanding of the impact and regulation of redox reactions in 
cancer with focus on the role of NOX2. The studies have comprised cells and animals 
that were genetically or pharmacologically deprived of NOX2 activity, and attempts were 
made to define the significance of the findings in a clinical setting. The results presented in 
paper I imply that ROS may inhibit the maturation of monocytes into antigen-presenting 
dendritic cells, which may favor tumor growth in vivo. Paper II reports that treatment 
of mice with the NOX2 inhibitor histamine dihydrochloride (HDC) resulted in reduced 
expansion and reduced immunosuppressive activity of myeloid-derived suppressor cells. 
Treatment of mice with HDC also improved the efficacy of checkpoint inhibitors to reduce 
the growth of murine lymphoma and colon cancer. The results of paper III suggest that 
HDC, by targeting NOX2-derived ROS, promotes the differentiation of acute myeloid 
leukemia (AML) cells in vitro and in vivo, thus implying that the intrinsic formation of 
ROS by AML cells contributes to their malignant features. In paper IV it is reported that 
functional NOX2 is relevant to the induction of chronic myeloid leukemia by murine BCR-
ABL1+ cells. In conclusion, these results support that NOX2 is a conceivable therapeutic 
target in cancer.
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ABSTRACT 
The reduction-oxidation (redox) reaction involves a change in the oxidation state 
of molecules where a molecule that donates an electron is oxidized and a molecule 
that accepts an electron is reduced. The NADPH oxidase of myeloid cells, NOX2, 
is a major source of oxidants in the form of reactive oxygen species (ROS), which 
are short-lived oxygen derivatives. NOX2-derived ROS have been ascribed a 
pivotal role in the elimination of pathogens and may be toxic also to host cells 
and tissues. ROS may also act as signaling molecules and thus regulate biological 
processes such as cell cycle proliferation, differentiation, cell death, blood vessel 
formation, and immunity. The purpose of this thesis was to contribute to the 
understanding of the impact and regulation of redox reactions in cancer with 
focus on the role of NOX2. The studies have comprised cells and animals that 
were genetically or pharmacologically deprived of NOX2 activity, and attempts 
were made to define the significance of the findings in a clinical setting. The 
results presented in paper I imply that ROS may inhibit the maturation of 
monocytes into antigen-presenting dendritic cells, which may favor tumor growth 
in vivo. Paper II reports that treatment of mice with the NOX2 inhibitor 
histamine dihydrochloride (HDC) resulted in reduced expansion and reduced 
immunosuppressive activity of myeloid-derived suppressor cells. Treatment of 
mice with HDC also improved the efficacy of checkpoint inhibitors to reduce the 
growth of murine lymphoma and colon cancer. The results of paper III suggest 
that HDC, by targeting NOX2-derived ROS, promotes the differentiation of 
acute myeloid leukemia (AML) cells in vitro and in vivo, thus implying that the 
intrinsic formation of ROS by AML cells contributes to their malignant features. 
In paper IV it is reported that functional NOX2 is relevant to the induction of 
chronic myeloid leukemia by murine BCR-ABL1+ cells. In conclusion, these 
results support that NOX2 is a conceivable therapeutic target in cancer. 
 
Keywords: Cancer, immunotherapy, reactive oxygen species, NOX2, histamine 
dihydrochloride, myeloid-derived suppressor cells, checkpoint inhibition, acute 
myeloid leukemia, chronic myeloid leukemia 
  
 SAMMANFATTNING PÅ SVENSKA 
Mer än var tredje person kommer under sin livstid att drabbas av cancer och 
cancer orsakar cirka 20 % av alla dödsfall i västvärlden. Traditionell 
cancerbehandling såsom kirurgi, cellgifter och strålning, har gjorts mer effektiv 
under de senaste årtiondena, vilket har bidragit till att prognosen har förbättrats 
vid flera cancerformer. Därtill har nyare behandlingar introducerats såsom att 
hämma cancercellers felreglerade proteiner eller att eliminera tillväxtfaktorer som 
cancerceller behöver för överlevnad. Denna avhandling handlar i första hand om 
immunoterapi, som är en sammanfattande benämning för behandlingar som avser 
att stimulera kroppens immunsystem till att avlägsna cancerceller.  
Immunsystemet omfattar celler med förmåga att eliminera cancerceller. Flera 
metoder har föreslagits för att farmakologiskt aktivera de immunceller som tycks 
vara mest effektiva mot cancerceller, d.v.s. cytotoxiska T-celler och natural killer 
(NK)-celler. Dessa cellers funktion är dock ofta undertryckt i tumörvävnad, p.g.a. 
hämmande signaler från cancerceller eller från tumörinfiltrerande myeloida celler. 
För att immunförsvaret mot cancerceller ska kunna aktiveras är det av vikt att 
identifiera och motverka dessa hämmande signaler. 
En sådan signal förmedlas av reaktiva syreradikaler (ROS) producerade av 
myeloiska celler, såsom makrofager och granulocyter, som ofta infiltrerar 
tumörvävnad. Om ROS bildas i en tumör kan T- och NK-celler inaktiveras och 
därmed riskerar behandling som aktiverar dessa celler att bli mindre effektiv eller 
verkningslös. Därtill kan vissa cancerceller, t.ex. vid akut och kronisk myeloisk 
leukemi (AML och KML), själva producera ROS vilket kan medföra att dessa 
celler undgår att elimineras av T- och NK-celler. Om ROS-produktion i tumörer 
hämmas kan därför immunstimulerande behandling vid cancer bli mer effektiv. 
ROS är därtill viktiga signalmolekyler i celler och modulerar proteiners funktion, 
men kan också skada DNA-molekyler så att mutationer uppkommer. 
Mitt avhandlingsarbete har syftat till att bidra till kunskap om hur ROS som bildas 
av ett enzym i myeloiska celler, NOX2, påverkar cancerutveckling. Jag har använt 
cancerceller och försöksdjur som modifierats genetiskt för att undertrycka NOX2 
samt substanser som hämmar NOX2-aktivitet. Resultaten talar för i) att NOX2 
har betydelse för dendritiska cellers funktion, som i sin tur är avgörande för T-
cellers funktion, ii) att NOX2-aktivitet undertrycker T-cellsfunktion i 
tumörvävnad, iii) att inhibition av NOX2 underlättar leukemicellers 
differentiering och därmed motverkar leukemi i försöksdjur, iv) att funktionellt 
NOX2 påskyndar utveckling av KML och v) att farmakologisk inhibition av 
NOX2 hämmar tumörtillväxt och därtill gör modern immunoterapi mer effektiv. 
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 1 
INTRODUCTION 
CANCER 
There exist more than 100 forms of cancer originating from various tissues and 
cell types, all with distinct characteristics. The transformation of a healthy cell to 
a malignant cell encompasses the acquisition of several features referred to as the 
“hallmarks of cancer” (1). These include sustained proliferation, resistance against 
apoptosis and immune cell destruction, invasion of adjacent tissues and the 
capacity to spread to other organs by metastasis, enhanced angiogenesis, 
deregulation of cellular energetics, and genomic instability (2). The characteristics 
of leukemias, cancers of blood-forming cells, differ from those of solid tumors in 
that leukemic cells rarely infiltrate tissues or form solid tumors in distant organs. 
 
The past decades have seen significant progress in the understanding of how 
mutations give rise to malignant tumors. In 1976, Peter Nowell forwarded the 
clonal evolution theory proposing that cancer development is a multistep process 
initiated by a primary mutation in a single cell followed by the acquisition of 
additional alterations in daughter cells resulting in a clonal disorder where the 
daughter cells are no longer genetically identical (3). While most genetic variants 
will be deleterious to the survival of the mutated cells, certain genetic alterations 
may provide potentially malignant cells with advantageous genotypes and 
phenotypes and following natural selection, the fittest subclones will prevail and 
expand (4). The occurrence of alterations in genes encoding proteins involved in 
the DNA repair system will result in genomic instability, escalating the rate of 
mutation in the cells (5). Sequential rounds of gained alterations and selection thus 
result in disease progression and the development of malignant tumors (4).  
 
In recent years, a hierarchy of malignant cells within a tumor has been proposed, 
leading to a new, or supplementary, theory referred to as the cancer stem cell 
(CSC) model. This theory is founded on the assumption that normal 
developmental programs are still valid during cancer progression and that the 
initial genetic alteration, providing a survival advantage, occurs in or gives rise to 
a cell with indefinite self-renewal capacity, i.e. a stem cell (6). Much of the current 
understanding of cancer evolution originates from advances in gene sequencing 
demonstrating the coexistence of malignant clones with diverse self-renewing 
capacity within tumors (7). Additionally, the development of fluorescence-
activated cell sorting (FACS) has allowed for the isolation of phenotypically 
distinct malignant cells.  
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Much of the early work demonstrating a hierarchical architecture of the malignant 
cells was performed in studies of malignant cells from patients with acute myeloid 
leukemia (AML). Phenotypically different AML cells were isolated and the initial 
results implied that only the CD34+CD38- leukemic cells, referred to as the 
leukemic-initiating cells (L-ICs), were capable of proliferation, differentiation, and 
unlimited self-renewal. The L-ICs initiated disease when transplanted to 
immunodeficient mice, and the evolving malignant cells comprised L-ICs as well 
as more differentiated leukemic cells, thus resembling those recovered from the 
patient from whom the cells originated (8). More recent experiments imply that 
also CD34+CD38+ leukemic cells may possess disease-initiating potential upon 
transplantation to immunodeficient mice under certain conditions, but the L-ICs 
are more rare among the CD34+CD38+ cells than in the CD34+CD38- population 
(9, 10). Since the identification of L-ICs in leukemias, malignant cells from various 
cancer types have been transplanted to immunodeficient mice leading to the 
documentation of tumor-initiating cells (T-ICs) in solid malignancies such as 
CD133+ cells in breast (11), brain (12), and colon cancer (13) and CD44+ cells in 
head and neck cancer (14). Collectively, these studies support that several 
malignancies are hierarchically organized where only rare cells have cancer-
initiating and propagating capacity. 
 
The seemingly consensual view is that the course of cancer is best described as a 
combination of the CSC model and the clonal evolution theory, which is 
sometimes referred to as the mixed model (Figure 1). Studies in leukemia have 
revealed that several subclones of L-ICs coexist and develop through clonal 
evolution and natural selection (15, 16). It has been suggested that early in the 
tumor development, the hierarchical model may best describe features of the 
tumor whereas upon disease progression, the T-ICs acquire and accumulate 
mutations in a process similar to that proposed in the clonal evolution theory. 
Hence, subclones of both T-ICs and non-T-ICs coexist and evolve in parallel (6, 
15, 16). The subclones may present with distinct driver mutations resulting in 
different capacities to e.g. multiply, form metastases, or induce angiogenesis. In 
addition, the localization of a tumor cell within the tumor microenvironment 
(TME) may have impact on its phenotype and stemness by altering what signaling 
molecules, such as nitric oxide (NO) and Wnt ligands, that the cancer cell is 
exposed to (17, 18). 
 
The increased understanding of the genetic and phenotypic diversity within 
tumors has unraveled differences in treatment responses between CSCs and the 
bulk of malignant cells. CSCs have, similar to healthy stem cells, been proposed 
to be quiescent and thus show reduced sensitivity to treatments that target 
proliferation such as chemotherapeutic agents (19). CSCs may also express drug 
efflux pumps, anti-apoptotic proteins, or have an efficient reactive oxygen species 
(ROS) scavenging system allowing for tolerance to increasing ROS levels in 
response to radiation and chemotherapy (20-22). Due to their tolerance to 
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traditional therapies and their potential to initiate disease, CSCs have been 
proposed as a principal cause of disease recurrence. In recent years, cancer 
immunotherapy has emerged as an additional option in cancer therapy that may 
fundamentally change the concept of cancer treatment allowing for selective 
targeting of CSCs (23, 24). 
 
 
Figure 1. Mixed model of cancer progression. The initial alteration, resulting in a proliferative 
advantage of the transformed cell, occurs in a cell with self-renewal potential. Additional genetic 
changes result in increased genomic instability and the generation of malignant subclones that 
further promote cancer progression. At the time of diagnosis, different subclones have evolved in 
a process involving selective pressure and natural selection. Treatment results in eradication of the 
bulk of tumor cells but a few T-ICs persist, which later cause disease recurrence and the regeneration 
of previously eradicated as well as new malignant clones. 
ACUTE MYELOID LEUKEMIA 
Genetic alterations in myeloid cells may initiate the development of AML where 
immature myeloid cells accumulate in the bone marrow (BM) and in peripheral 
tissues. AML is genetically heterogenous and the leukemic cells may harbor an 
abnormal karyotype because of e.g. gene translocations and deletions but may also 
carry a normal karyotype with genetic mutations as drivers of the disease (25). 
These genetic alterations provide a proliferative advantage to the leukemic cells 
and cause a block in myeloid differentiation. Depending on the genetic alteration, 
the block in differentiation may occur at different stages of hematopoiesis leading 
to different maturity and disease characteristics of the predominant leukemic 
clone (26).  
 
Traditionally, the French-American-British (FAB) classification system has been 
employed to classify AML based on the phenotypic characteristics of the 
predominant malignant clone, resulting in eight subtypes of AML referred to as 
M0-M7 (27). In recent years, the World Health Organization (WHO) 
classification system, which is based on the specific genetic abnormalities of the 
leukemic cells, has largely replaced the FAB classification system. The WHO 
classification system has proven to better prognosticate disease outcome, since 
Healthy
tissue
Genomic
instability
Treatment
Incomplete
eradication of
T-ICs
Disease
recurrence
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specific genetic alterations often are associated with prognosis (28). Hence, the 
genomic landscape of the leukemic cells is taken into consideration in the decision 
to proceed to allogeneic hematopoietic stem cell transplantation (allo-HSCT) after 
initial treatment with high doses of chemotherapy. Allo-HSCT is reportedly only 
beneficial in intermediate- and high-risk leukemia with, for example, FMS-like 
tyrosine kinase-3 internal tandem duplications (FLT3-ITD) mutation, KMT2A 
rearrangement, mutated TP53, or RUNX1 mutations (25, 29). 
 
The treatment of AML typically includes cycles of high doses of chemotherapy. 
Chemotherapy given at diagnosis is denoted induction therapy and aims at 
achieving complete remission (CR), defined as the disappearance of leukemic cells 
and reestablished normal hematopoiesis (25, 26). Approximately 70-80 % of 
patients <60 years old and 45-60 % of older patients will attain CR after induction 
therapy (30). However, the vast majority of patients will experience relapse of 
AML in the absence of further treatment. Therefore, induction therapy is 
followed by a consolidation phase of chemotherapy aiming at eradicating residual 
and non-detectable leukemic cells to reduce the risk of relapse (31). Allo-HSCT 
may follow consolidation therapy in intermediate- and high-risk group patients to 
further increase the likelihood of disease-free survival (25). Despite the aggressive 
treatment in AML the prognosis is relatively poor with 40 % of younger (<60 
years) and 10 % of older patients being long-term survivors (30). 
 
Several targeted therapies aiming at improving survival in AML are currently 
being evaluated, including FLT3 inhibitors (32), inhibitors of isocitrate 
dehydrogenase (33), and bi-specific antibodies directed towards AML-specific 
antigens (34). Midostaurin and enasidenib, which target FLT3 and isocitrate 
dehydrogenase-2, respectively, were recently approved by the US Food and Drug 
Administration. Targeted therapy is also available for a subgroup of AML, acute 
promyelocytic leukemia (APL), which is characterized by a fusion protein 
between retinoic acid receptor D  (RARD) and promyelocytic leukemia protein 
(PML) resulting from a translocation between chromosome 15 and 17. The 
RARD-PML fusion protein interferes with retinoic acid signaling, resulting in 
altered gene transcription and a blocked differentiation. Treatment with all-trans 
retinoic acid (ATRA) has dramatically improved prognosis in this group of 
patients with cure rates exceeding 80 %. In recent years, the addition of arsenic 
trioxide has been shown to further enhance the efficacy of ATRA in APL (35). 
 
Additionally, immunotherapies aiming at stimulating the anti-leukemic efficacy of 
cytotoxic natural killer (NK) cells and T cells have been evaluated in AML, 
including NK cell infusions (36), stimulatory cytokines such as interleukin 2 (IL-
2), and the combination of IL-2 with histamine dihydrochloride (HDC) that 
reduces the production of immunosuppressive ROS (37, 38). HDC/IL-2 is 
approved as post-consolidation immunotherapy in Europe and remains the only 
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non-transplant therapy that has reduced the risk of relapse in the post-
chemotherapy phase of AML in a phase III trial (37). The results of post-hoc 
analyses imply that treatment with HDC/IL-2 improves leukemia-free survival in 
AML patients harboring leukemic cells that express functional histamine H2 
receptors (H2R) and the ROS-forming myeloid nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (NOX2) (FAB-M4 and -M5 AML) (39). In these 
patients, the treatment may act by inhibiting the formation of leukemia-derived 
ROS via H2R expressed by leukemic cells, thus protecting immune cells from 
ROS-induced toxicity in the leukemic microenvironment (37, 39). 
CHRONIC MYELOID LEUKEMIA 
Chronic myeloid leukemia (CML) is, in contrast to AML, a genetically and 
morphologically homogeneous disease where >98 % of patients harbor mature 
granulocytes carrying a reciprocal chromosomal translocation between 
chromosome 9 and 22, referred to as the Philadelphia chromosome (40-42). The 
Philadelphia chromosome results in the formation of an oncogene on 
chromosome 22 known as breakpoint region protein-abelson murine leukemia 
viral oncogene homolog 1 (BCR-ABL1), and the reciprocal gene ABL1-BCR on 
chromosome 9. Both genes may be transcriptionally active but only BCR-ABL1 
contributes to the initiation and maintenance of leukemia (41, 43). Expression of 
BCR-ABL1 results in a constitutively active ABL1 tyrosine kinase that promotes 
the survival of the BCR-ABL1+ cells (44). Although the malignant cells are 
granulocytes, the BCR-ABL1 translocation may be found in a variety of cell types 
in the periphery suggesting that CML, as proposed by the CSC model, is a stem 
cell disease arising from the acquisition of the BCR-ABL1 translocation in a 
hematopoietic stem or early progenitor cell (45). 
 
If untreated, CML progresses through a chronic phase (ongoing for several years), 
an accelerated phase (typically lasting 4-6 months), and a final stage resembling 
acute leukemia (blast crisis). Most patients are diagnosed in the chronic phase by 
the detection of mature BCR-ABL1+ granulocytes in blood. Upon disease 
progression, the BCR-ABL1+ leukemic progenitor cells acquire additional 
mutations that may result in rapid accumulation of malignant blasts in blood and 
BM. The blast crisis in CML is characterized by a differentiation arrest and a 
disease more akin to that of AML and thus requires induction and consolidation 
chemotherapy. However, the blast crisis may also be dominated by lymphocytic 
leukemic cells (46, 47).  
 
In the past, CML was a disease with dismal long-term prognosis, but the 
introduction of the first-generation tyrosine kinase inhibitor (TKI), imatinib, 
revolutionized the treatment and dramatically improved prognosis (48). The life-
expectancy of patients with CML is nowadays close to that of the general 
population provided that TKI treatment is initiated in the chronic phase of the 
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disease (48, 49). Imatinib competes with adenosine triphosphate (ATP) for a 
binding site on ABL1 and thereby efficiently inactivates the kinase activity of the 
oncoprotein (50). The early treatment response to imatinib is optimally monitored 
by measuring BCR-ABL1 transcripts in blood after treatment initiation and are 
important indicators of prognosis (51). Imatinib has since 2002 been the standard 
of care and first-line therapy in CML, but imatinib intolerance or resistance have 
led to the development and approval of second- and third-generation TKIs such 
as nilotinib, dasatinib, bosotinib, and ponatinib (52).  
 
The second- and third-generation TKIs are more potent with a shorter time to 
reach early and optimal molecular responses along with lower risk of disease 
progression. However, with these more potent inhibitors, tolerability and toxicity 
have become increasingly problematic (53). Thus, despite a reduction in CML-
related deaths, the overall survival after treatment with second- or third-
generation TKIs remains the same as that in patients receiving imatinib, likely due 
to increased non-CML related mortality (54). Imatinib hence remains the first-
line treatment of CML but the new inhibitors are valuable tools for high-risk 
group patients and for patients that progress despite imatinib treatment.  
 
Over 90 point mutations in the kinase domain of ABL1 have been identified 
leading to resistance to imatinib. In this regard, the T315I mutation is the most 
frequent and also results to resistance to nilotinib, dasatinib, and bosotinib. 
Ponatinib was developed to retain TKI activity in the presence of the T315I 
mutation. For patients progressing on imatinib it is therefore important to identify 
kinase mutations in order to select for optimal TKI substitutes. Ponatinib is also 
efficacious in heavily pretreated patients who have failed to achieve major 
molecular responses after receiving first- and second-generation TKIs (55).  
 
Despite the efficacy of TKIs in eradication of the bulk of the malignant cells, the 
L-ICs in CML are seemingly not dependent on the expression of BCR-ABL1 for 
their survival and thus prevail in most patients (56, 57). Therefore, TKI therapy 
has been considered to be life-long with high societal costs and significant 
morbidity. In recent years, the possibility to safely discontinue TKI therapy has 
been increasingly explored and a significant fraction of patients will remain in 
leukemia-free remission after TKI discontinuation. The time on TKI before 
treatment discontinuation and the depth of molecular response at TKI withdrawal 
are predictive for disease-free survival (58). TKI discontinuation has not been 
associated with major safety concerns as relapsing patients almost invariably 
regain major molecular response after restarting TKI therapy (59, 60). Several 
investigators are currently aiming at identifying strategies that increase the fraction 
of patients who will remain leukemia-free after TKI withdrawal, including 
attempts to eliminate L-ICs before TKI cessation (61).  
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THE IMMUNE SYSTEM 
The immune cells that contribute to the defense against pathogens and 
transformed cells may be divided into innate immune cells, with germ-line 
encoded receptors recognizing a fixed set of antigens, and adaptive immune cells, 
with a broader antigen-specificity due to genetic recombination of the receptors 
in individual somatic cells. Upon infection, innate tissue-resident macrophages 
sense and respond to a pathogen following the secretion of cytokines that recruit 
additional phagocytes to the site of infection. Phagocytes, foremost dendritic cells 
(DCs), are additionally responsible to evoke an adaptive immune response. After 
antigen uptake, DCs thus migrate to the closest secondary lymphoid organ where 
the antigens are presented to induce the activation of T cells and B cells, 
recognizing the same antigens, in a highly controlled process.  
NEUTROPHILS 
Neutrophils, or polymorphonuclear granulocytes, are the most abundant 
leukocytes in blood and an important effector cell of innate immunity (62). Upon 
infection, tissue-resident macrophages will secrete factors that stimulate epithelial 
cells in the vessel walls to upregulate adhesion molecules allowing for neutrophil 
extravasation, in addition to chemotactic factors that will guide neutrophils to the 
site of infection (63). Neutrophils are hence one of the first cell types mobilized 
at the site of infection. The expression of a variety of pattern recognition 
receptors, with specificity for molecules common for many pathogens, allows 
neutrophils to respond to invading microorganisms via activation of among other 
transcription factors nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-NB). NF-NB signaling activates the neutrophils to secrete pro-
inflammatory cytokines, chemokines, and adhesion molecules that orchestrate the 
immune response (64). The main effector function of neutrophils is phagocytosis 
by which they engulf pathogens for internal degradation in a process highly 
dependent on the expression of the ROS-generating oxidase NOX2 in the 
phagosomal membranes. Cell membrane-bound NOX2 also allows for 
extracellular release of ROS and degradation of surrounding pathogens. 
Neutrophils can also eject networks of DNA and bactericidal proteins to trap a 
pathogen in a process called neutrophil extracellular traps (63, 64).    
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MONOCYTES 
Monocytes develop from BM precursors when exposed to macrophage colony-
stimulating factor (M-CSF) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (65, 66) and are subdivided into classical and alternative 
monocytes (67). Both subtypes express CD11b in humans and mice whereas only 
human monocytes carry CD14 (68). Classical and alternative monocytes show 
different surface expression profiles. In humans, classical monocytes are defined 
as CD14highCD16- cells whereas alternative monocytes are CD14dimCD16high (67). 
The expression level of Ly6C is used to distinguish classical and alternative 
monocytes in mice where classical monocytes show a high expression of Ly6C 
whereas alternative monocytes are Ly6Cdim (69).  
 
At homeostasis, monocytes are found in the blood but the largest pool of 
monocytes resides in the BM and spleen (70). Distinct mechanisms are involved 
in the recruitment of monocytes to the periphery during inflammation. The 
chemokine (C-C motif) ligand 2 and 7 (CCL2 and CCL7, respectively), which are 
strongly upregulated in inflammation, are involved in the recruitment of classical 
monocytes from the BM to the periphery (71). Upon further stimulation, e.g. 
induced by infection, classical monocytes migrate from the blood stream to 
infectious tissues where they differentiate into macrophages or, in certain settings, 
into monocyte-derived DCs (72, 73). 
 
Alternative monocytes are believed to have a more patrolling role characterized 
by crawling along the surface of small vessels to sample their surroundings to 
identify dying or infected cells and effectuate their removal (73). The alternative 
monocytes have also been suggested to contribute in defense against cancer 
metastasis (74). In mice, the alternative monocytes express CX3-chemocine 
receptor 1 and their recruitment thus relies on the secretion of chemokine (C-X3-
C motif) ligand 1 (75). Functional aspects of alternative monocytes have mainly 
been studied in mice and the functionality of these cells may differ in humans. 
However, in both mice and human, alternative monocytes may differentiate from 
classical monocytes (73). 
MACROPHAGES  
Macrophages are large phagocytic cells that reside in essentially all tissues 
throughout the body. Depending on the tissue in which these cells reside they 
gain distinct functions with individual names such as the Kupffer cells in the liver 
and the microglial cells in the nervous system. The main function of macrophages 
is to rapidly mobilize an immune response towards an invading pathogen by 
recruiting cells of both innate and adaptive immunity to the site of infection. 
Macrophages express a battery of surface receptors recognizing structures of 
potential pathogens such as toll-like receptors (TLRs), nucleotide-binding 
oligomerization domain-like receptor, and, in humans, the lipopolysaccharide 
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receptor CD14 (76). Upon interaction of a receptor with its ligand a signal cascade 
results in macrophage activation mainly through activation of NF-NB with 
ensuing secretion of cytokines that recruit additional effector cells, including 
neutrophils, to the site of infection (77). Macrophages also play a crucial role in 
the host’s early attempt to eradicate a pathogen owing to their capacity to exert 
phagocytosis where pathogens are engulfed and exposed to toxic, lysosomal ROS 
formed by NOX2. The mannose receptor CD206 and scavenger receptors are 
involved in the initiation of phagocytosis. Later in the inflammatory process 
macrophages may also aid in activation of adaptive immunity through antigen 
presentation to T cells (76). 
 
Macrophages are, similarly to monocytes, divided into distinct populations 
referred to as M1, classically activated, and M2, alternatively activated 
macrophages. The M2 macrophages are further divided into M2a, M2b, and M2c 
subtypes. M1 macrophages are activated by interferon-J (IFN-J) mainly produced 
by T helper 1 (TH1) lymphocytes and NK cells. Exposure of macrophages to IFN-
J enhances their release of ROS (78). In addition to ROS production, inducible 
nitric oxide synthase (iNOS) that forms NO is an important mediator of M1 
immunity (77). M2 macrophages have instead been ascribed a role in defense 
against parasites and contribute to debris scavenging, angiogenesis, wound 
healing, and downregulation of immune responses, in part by producing IL-10 
(77). Activation of M2 macrophages is achieved mainly by IL-4 (79), IL-13 (80), 
and IL-10 signaling (81). While details of the respective functions of M1 and M2 
macrophages remain to be defined, M2-mediated immune responses are 
considered more immunosuppressive whereas M1 immunity is considered 
immune-activating.  
 
Traditionally, macrophages were believed to derive from BM- or blood 
monocytes (82). In recent years, evidence has however been presented supporting 
that tissue-resident macrophages may also be yolk sac-derived or stem from 
embryonic progenitors that entered tissues before birth, where they retain the 
pool of tissue-resident macrophages throughout adulthood (83). While embryonic 
progenitor cells are important for the maintenance of tissue-resident macrophages 
at steady state, blood-derived monocytes are considered to be the precursors of 
macrophage expansion in inflammation (84).  
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DENDRITIC CELLS 
DCs, macrophages, and B cells are referred to as professional antigen-presenting 
cells (APCs). Among those, DCs are the most efficacious APC and hence provide 
an important bridge between innate and adaptive immunity. Similar to 
macrophages, DCs express a range of receptors for pathogen recognition and are 
specialized in the uptake, processing, and presentation of antigens on major 
histocompatibility complex (MHC) class I and II (76). DCs may be divided into 
plasmocytoid DCs (pDCs) and conventional DCs (cDCs) which can be further 
categorized as cDC1 and cDC2 populations (85, 86). The pDC, cDC1, and cDC2 
populations have distinct characteristics and phenotypes that are highlighted in 
Figure 2.  
 
At steady state, pDCs are circulating cells with a poor capacity to present antigen 
but acquire a DC-like morphology along with the ability to process and present 
antigen upon viral stimulation. These DCs can also produce high levels of type I 
interferons (IFN-DE) that exert antiviral activity and may activate NK cells and 
macrophages (87). pDCs are also present as resident DCs in lymphoid organs. 
 
The cDC1 and cDC2 populations may be either migratory or lymphoid tissue-
resident. The migratory cDCs patrol peripheral tissue and sample their 
surrounding for antigens to be presented to T cells after migration to the nearest 
lymph node. Upon encountering a microbial antigen, cDCs become activated 
resulting in the upregulation of co-stimulatory molecules, to enhance their T cell-
activating properties, and an increased expression of C-C chemokine receptor 
type 7 (CCR7), which enhances the capacity of the cDC to migrate to lymph 
nodes. In this process, cDCs elaborate dendrites that allow for more efficient 
interactions with T cells. Activation of cDCs also comprises a reduction in their 
capacity to engulf, process, and present additional antigens. Once in the lymph 
node, the cDCs localize to the cortical T cell area and secret CCL18 to attract T 
cells. cDCs can produce a wide range of cytokines including type III interferons 
(IFN-O), IL-12, IL-23, IL-10, and transforming growth factor-E (TGF-E) that 
direct polarization of helper T cell populations (76, 85, 86, 88). 
 
Lymphoid tissue-resident cDCs are sentinels of the lymphoid organs and are 
restricted to a specific lymphoid organ throughout their life span. Whereas 
migratory cDCs are mature upon arrival to a lymphoid organ, lymphoid tissue-
resident cDCs reside in the lymphoid tissues in an immature state and their 
maturation is initiated only after antigen uptake in the lymphoid organs (89). 
Lymphoid tissue-resident cDCs are essential during infections that infect DCs 
themselves such as influenza virus. Under such circumstances, the migratory 
cDCs carrying the antigen to the lymph node may be killed by the infection. The 
antigen can thus be transferred to a healthy lymphoid tissue-resident cDC that 
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has a retained antigen-presenting machinery allowing for proper T cell activation 
(76, 86, 89).  
 
In an inflammatory setting, a supplementary entity of DCs is believed to be 
generated from monocytes that enter the site of inflammation and differentiate 
into inflammatory monocyte-derived DCs (85, 86). Inflammatory DCs, or 
monocyte-derived DCs, are suggested to participate in the innate immune defense 
and T cell activation. These cells have been suggested to reinforce and replace the 
function of cDCs during uncontrolled infections (69, 90).  
 
 
Figure 2. DC subsets. DCs are classified into three main populations namely plasmacytoid DCs 
(pDCs), conventional DC1s (cDC1s), and conventional DC2s (cDC2s). The subpopulations are 
specialized on shaping T cell immunity in response to different types of infections resulting in the 
activation of cytotoxic CD8+ T cells (CD8+), CD4+ helper T cells (TH1, TH2, TH17), or regulatory 
T cells (Tregs). 
ANTIGEN PRESENTATION 
APCs are defined by their ability to present antigens on MHC class I and class II. 
In general, intracellular antigens are presented on MHC class I to CD8+ T cells, 
while MHC class II presents extracellular antigens to CD4+ T cells. Whereas all 
nucleated cells present intracellular peptides on MHC class I, only professional 
APCs are capable of also presenting extracellular antigens on MHC I. 
Additionally, presentation of peptides on MHC class II is also restricted to 
professional APCs.  
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Intracellular
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Presentation on MHC class II involves the uptake of extracellular antigens 
through phagocytosis to endocytic vesicles. The endosomes will fuse with 
lysosomes generating endolysosomes in which the phagocytosed material is 
degraded into peptides. Newly synthesized MHC class II cargo vesicles fuse with 
the endolysosomes allowing the degraded peptides to attach to MHC class II. 
Complexes with MHC class II molecules and adherent peptides later translocate 
to the cell membrane where the MHC class II and associated peptide is presented 
to CD4+ T cells to evoke adaptive immunity (76, 91-93). 
 
All nucleated cells present their intracellular protein content on MHC class I, 
which is an essential mechanism for the identification of infected or transformed 
cells by activated cytotoxic T cells. The normal mode of presentation of peptides 
on MHC class I involves the degradation of endogenous proteins by cytosolic and 
nuclear proteasomes. The peptides produced during this process are translocated 
to the endoplasmic reticulum where they bind to the peptide-binding groove of 
MHC class I molecules following transport through Golgi to the cell membrane 
for activation of CD8+ T cells. For the activation of naïve CD8+ T cells the 
presentation of peptides on MHC class I needs to be accompanied by 
costimulation, which only professional APCs are capable of providing. 
 
Furthermore, as stated above, certain types of APCs, foremost cDC1s, have the 
ability to process phagocytosed antigens and load peptides derived from the 
exogenous proteins on MHC class I molecules. This process of antigen 
presentation is termed cross-presentation. Whereas the processes resulting in the 
presentation of endogenous peptides on MHC class I and exogenous peptides on 
MHC class II are well established, the underlying mechanism for cross-
presentation is less well understood. Cross-presentation has been suggested to 
occur either via a vacuolar pathway or a cytosolic pathway or a combination of 
both these pathways. The initial step in cross-presentation is endocytosis of 
exogenous antigens to a phagocytic vesicle. Thereafter antigens are either 
degraded and bound to MHC I within the phagolysosome (vacuolar pathway) or 
exported to the cytoplasm before being degraded by proteasomes and loaded on 
MHC I (cytosolic pathway) (76, 91, 93-95).  
 
Peptides that are to be cross-presented on MHC class I need to be protected from 
complete lysosomal degradation. NOX2 is recruited to the DCs early phagosomes 
and produce low levels of ROS in the lysosomal lumen that consumes protons 
and thus leads to alkalization of the lysosome. The reduced pH in the lysosomes 
inhibits lysosomal proteases which reduce degradation of exogenous antigens, 
and thus enhances cross-presentation (96-98).  
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T CELLS 
Immature T cells, which are formed in the BM from lymphoid progenitors, 
complete their maturation to become naïve T cells in the thymus. The T cell 
progenitors first lose their stem cell markers, but do not express the T cell markers 
CD4 or CD8 and are thus referred to as double-negative thymocytes (99). The 
double-negative thymocytes will initiate the rearrangement of the genes encoding 
for the D, E, J, and G subunits of the T cell receptor (TCR). Rearrangement of the 
D- and J-chains involves variable, joining, and constant regions whereas the E- 
and G-chains also include diversity gene segments. During gene rearrangement 
these segments are recombined and addition, deletion, or substitution of 
nucleotides occurs. In this fashion, the relatively small set of genes encoding TCR 
segments generates a highly diverse pool of T cells (100), each with an unique 
antigen specificity. Gene rearrangement commits the T cell to either an D:E or a 
J:G T cell where the most frequent outcome is the generation of an D:E T cells, at 
this stage, expressing both CD4 and CD8 and are thus referred to as a double-
positive thymocytes (76, 101, 102).      
 
Once the TCR is in place, the T cell is subjected to positive selection where only 
T cells that recognize self-MHC class I or II molecules receive survival signals 
allowing them to continue their development (76, 103). Following positive 
selection, which also commits the T cells to the CD4+ or CD8+ linage, DCs 
mediate a process in which T cells recognizing self-antigens are eradicated 
referred to as negative selection (104, 105). Cells that have completed positive and 
negative selection are denoted naïve and are small non-dividing cells that circulate 
between the blood, the lymph, and the secondary lymphoid organs (106, 107). In 
the secondary lymphoid organs the naïve T cell will roll alongside DCs to seek for 
the peptide:MHC complex corresponding to its TCR. If the naïve T cell does not 
encounter a cognate peptide:MHC it will continue circulating in an inactive state, 
which can endure for years. In the opposite scenario, the naïve T cell finds its 
complementary peptide:MHC complex and is retained in the node until it has 
become fully activated.  
 
Activation of a naïve T cell includes the interaction between the cognate TCR and 
a peptide:MHC complex, CD4 or CD8 with MHC class II or I, and costimulation 
via for example CD80 and CD86 expressed by the APCs and CD28 expressed by 
the naïve T cell (108). In addition, cytokines produced by the APCs are important 
to modulate T cell activation and direct T cell polarization. These APC-derived 
signals result in the activation of several aspects of T cells, including the formation 
of IL-2, which triggers T cell proliferation and thus promotes clonal expansion of 
the selected T cell (109-111). Once the T cells have undergone complete 
activation they will leave the secondary lymphoid organ and migrate via the blood 
to the site of infection to combat the pathogen. T helper 2 (TH2) cells that may 
aid in B cell immunoglobulin class switching can however remain in the secondary 
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lymphoid organs allowing them to interact with passing B cells. The development 
and activation of T cells is depicted in Figure 3. 
 
 
Figure 3. T cell development, activation, and function. The early T cell development takes 
place in the thymus where double negative thymocytes (dn-thymocytes) through a process involving 
gene rearrangement and positive and negative selection generates single positive (sp) CD4+ or CD8+ 
T cells. The naïve T cells are released from the thymus and will circulate between blood, lymphatic 
vessels, and secondary lymphoid tissues, until encountering an APC presenting its cognate peptide. 
The activated T cells mediate various effector functions. TH2 cells can induce IgE antibody 
switching in B cells, stimulate eosinophils and mast cells, or polarize macrophages (MQ) to the M2 
lineage. TH1 cells produce IFN-J that enhances expression of MHC, enhances macrophage 
activation and M1 polarization, and induces IgG2a and IgG3 antibody class-switch in B cells. 
Activated CD8+ T cells can kill virus-infected or malignant cells. 
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CD4+ T CELLS 
CD4+ T cells act either by down-regulating immune responses, as for the 
regulatory T cells, or by boosting the activity of other immune cells, as for helper 
T cells such as TH1, TH2, or TH17 CD4+ T cells. TH1 T cells are important in the 
defense against infectious agents that reside in the phagosomes of macrophages. 
The TH1 T cells produce IFN-J, tumor necrosis factor (TNF), and IL-2. In 
particular IFN-J is known to have antiviral, immunoregulatory, and anti-tumor 
properties, via induction of MHC molecules on APCs and normal cells. 
Additionally, IFN-J increases activation and differentiation of macrophages and 
also induces IgG2a and IgG3 antibody switch in B cells (76, 112). The functions 
of TH2 cells include activation of M2 macrophages, eosinophils, mast cells, and 
antibody isotype switching to IgE through the production of IL-4, IL-5, IL-9, and 
IL-13 (113). The TH17 cells produce and secrete IL-17 and are believed to be pro-
inflammatory by helping epithelial cells and fibroblasts to recruit inflammatory 
cells to the site of infection (76, 112, 114). 
 
The main function of regulatory CD4+ T cells (Tregs) is to dampen immune 
responses by suppressing CD4+ and CD8+ T cells. Tregs produce large quantities 
of immunosuppressive and anti-inflammatory cytokines such as IL-4, IL-10, and 
TNF-E, but their immunosuppressive features are also dependent on the 
expression of cytotoxic T lymphocyte antigen 4 (CTLA-4) (76, 115, 116). 
CD8+ T CELLS 
Activated CD8+ T cells show increased expression of adhesion molecules that 
facilitate their interactions with target cells. Hence, activated, but not resting, 
CD8+ T cells form an immunological synapse when encountering cells presenting 
their matching peptide in the context of MHC class I even in the absence of 
costimulation (117). The activation of effector CD8+ T cells results in the 
production of IFN-O and cytotoxins, such as perforin and granzyme B, that are 
packed into lytic granules. Once the CD8+ T cell releases its lytic granules in the 
synaptic cleft, perforin will create pores in the target cell membrane allowing 
granzyme B to translocate into the cytosol where it will induces apoptosis by 
cleaving caspases (118, 119). CD8+ T cells are serial killers and may proceed to 
kill additional cells when new lytic granules have been synthesized.  
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NK CELLS 
Natural killer (NK) cells are derived from BM precursors and are phenotypically 
defined as cells lacking the expression of CD3 while expressing CD56. 
Subdivision of NK cells is based on the expression level of CD56 and CD16. The 
immature CD56brightCD16dim NK cells are considered precursors of the more 
differentiated CD56dimCD16bright NK cells, which are endowed with higher 
cytotoxic capacity (120). NK cells are innate lymphocytes that identify and 
eradicate transformed or virus-infected cells but are also an important source of 
cytokines and chemokines. A target cell is recognized by a NK cell by its ligand 
expression profile where a variety of ligands either impede or stimulate the 
cytotoxicity of the NK cell. Thus, when a NK cell interacts with a potential target 
cell the balance between inhibitory and activating stimuli will determine the 
outcome of the interaction. Consequently, a target cell expressing more activating 
than inhibitory ligands will trigger the NK cell to form an immunological synapse 
with the target cell into which the NK cell releases its granules. Similar to CD8+ 
T cells, NK cell-derived granule contain perforin and granzyme B that induce an 
apoptotic cascade in the target cell (121). NK cells may also express membrane-
bound death-ligands, such as TNF-related apoptosis-inducing ligands (TRAILs) 
and Fas ligands, which may induce caspase-dependent apoptosis of target cell 
(122). In contrast to T cells, NK cells do not require any prior sensitization and 
may mobilize a rapid immune response upon encountering infected or 
transformed cells, dependent on their ligand expression profile.  
 
While downregulation of MHC class I on aberrant cells is a mechanism by which 
an infected or a malignant cell may avoid CD8+ T cell-mediated immunity, a 
reduced expression of MHC class I renders a target cell more susceptible for NK 
cell identification, which is referred to as the “missing-self” model (123). The 
expression of MHC class I provides an inhibitory signal to NK cells expressing 
NKG2A and certain types of killer-cell immunoglobulin-like receptors (KIRs). 
The ability of NK cells to reject MHC class I-deficient cells thus provides a second 
level of protection against virus-infected and transformed cells in case of 
inadequate eradication by CD8+ T cells. The “missing-self” model does 
nevertheless not explain why autologous MHC class I-deficient cells, such as 
erythrocytes, are not depleted by NK cells. However, a reduced expression of 
inhibitory receptors is not sufficient to promote NK cell activation. Instead, the 
target cell also needs to express activating ligands, such as stress ligands that are 
frequently upregulated on virally infected and malignant cells or proteins 
associated with viral and bacterial infections or tumor cells. These ligands engage 
activating receptors, such as NKG2D or natural cytotoxicity receptors (including 
NKp46 and NKp30), on NK cells. Thus, the balance between activating and 
inhibiting stimuli received by the NK cell from the target cell determines the 
outcome of the interaction (124-126).  
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Additionally, CD16 which is an Fc receptor allows CD16+ NK cells to attach to 
the constant region of antibodies. Target cells coated with antibodies may thus 
trigger NK cell activation in a process denoted antibody-dependent cellular 
cytotoxicity (ADCC).  
B CELLS 
B cells develop from precursor cells in the BM where also positive and negative 
selection of the B cell receptor occurs. The final stages of maturation, to become 
naïve BM cells, occurs in the secondary lymphoid organs. Naïve BM cells circulate 
between blood and lymphoid organs and are responsive to antigens binding to 
their B cell receptor. Upon encountering with an antigen recognized by the 
cognate B cell receptor the B cell becomes activated and with help from B 
follicular helper T cells and follicular DCs the B cells differentiates into antibody 
producing plasma cells (127). Activated B cells secrete antibodies and are referred 
to as plasma cells. The synthesized antibodies may neutralize bacterial toxins or 
opsonize bacteria to stimulate ADCC and thereby aid in elimination of pathogens 
(76).  
REACTIVE OXYGEN SPECIES 
ROS are oxygen-derived chemicals that oxidize other compounds (i.e. “steal 
electrons”). ROS include radicals, with unpaired valence electrons, like superoxide 
(O2•-) and hydroxyl anion (•OH), and non-radicals with similar oxidizing capacity, 
such as hydrogen peroxide (H2O2), hypochlorous acid, ozone, and singlet oxygen 
(128, 129). The non-radical H2O2 may be converted to hydroxyl radicals in the 
presence of ferrous ions in a process referred to as the Fenton reaction. Another 
highly reactive oxidant, peroxynitrite, is formed in a reaction between superoxide 
and nitric oxide synthase (NOS)-derived NO (130). ROS are produced in 
response to exogenous or endogenous stimuli. ROS may thus be generated from 
tobacco, smoke, pollutants, ionizing radiation, formed as bi-products during 
oxidative respiration, or specifically by radical-generating enzymes such as the 
NADPH oxidases (NOXs) and xanthine oxidase.  
 
ROS have multiple physiological and non-physiological functions within cells.  In 
phagocytes, NOX2-derived ROS contribute to eradication of pathogens within 
the phagolysosome. Accordingly, patients with genetic NOX2 deficiency are at 
high risk of developing recurrent bacterial and fungal infections (131). ROS may 
also serve as signaling molecules by turning on or off the activity of various 
proteins in redox reactions. An advantage of ROS as regulatory molecules is their 
short half-life time and that some ROS, such as H2O2, can diffuse across 
biological membranes allowing for the control of protein functions intra- and 
extracellularly. ROS act as regulatory molecules by reversibly oxidizing cysteine 
 18 
residues within proteins. At physiological pH, cysteine residues exist as thiol 
anions (Cys-S-) that are easily oxidized into Cys-OH with a resulting allosteric 
change of the protein structure and an altered function. Cys-OH is reduced to its 
original form by disulfide reductases resulting in restored protein function. A 
setting in which the ROS levels exceed the antioxidative defense system is referred 
to as oxidative stress. During oxidative stress, the redox balance is tilted towards 
more of the oxidized variants of cysteines and ROS may thus inflict permanent 
tissue damage by oxidizing proteins, lipids, carbohydrates, or nucleic acids (130, 
132). Several cellular systems exist with the purpose of neutralizing radicals and 
non-radicals, thus protecting cells from ROS-induced damage. The most 
powerful enzymatic scavengers of ROS include superoxide dismutase, catalase, 
peroxiredoxins, glutathione peroxidase-1, and thioredoxin (133).  
MITOCHONDRIAL ROS 
The mitochondria are a main source of cellular ROS. The mitochondrion is a 
double-membrane organelle localized in the cytosol of cells and is responsible for 
generating energy in the form of ATP through the oxidation of carbohydrates and 
fatty acids in a process denoted oxidative phosphorylation. During this process, 
electrons pass through the electron transport chain via redox reactions while 
releasing energy in the form of ATP (134). The final electron acceptor is molecular 
oxygen, most of which is converted into water. However, superoxide is produced 
as a bi-product due to incomplete reduction of oxygen to water. Accordingly, 
mitochondria harbor the highest levels of antioxidants in a cell to protect from 
superoxide produced during ATP generation. 
NOX-DERIVED ROS 
Seven NADPH oxidases have been identified: NOX1-5 and DUOX1-2. The 
NOX family of oxidases share the capacity to transfer electrons across biological 
membranes to generate ROS but differ in distribution between cell types and in 
subcellular localization (135). NOX1 is most highly expressed in the colon, 
NOX2 in phagocytes, NOX3 in the inner ear and in fetal tissues, NOX4 in the 
kidney, NOX5 in lymphoid tissues and testis, and DUOX1-2 in the thyroid tissue 
and in the gastrointestinal tract. 
 
NOX2 consists of membrane-bound (gp91phox, also referred to as NOX2, and 
p22phox) and cytosolic (p67phox, p47phox, p40phox, and Rac) subunits where the 
membrane-bound subunits encompass the catalytic function of the oxidase. 
gp91phox and p22phox constitutively interact to form a membrane-bound complex 
referred to as flavocytochrome b558 but the activation of the oxidase requires 
translocation of the cytosolic subunits to the membrane. Activation of NOX2 
may be induced by growth factors, cytokines, or interactions involving pathogen-
associated molecular patterns, damage-associated molecular patterns, or bacterial 
peptides that result in the phosphorylation of p47phox. At rest, p40phox and p67phox 
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are generally associated in the cytosol. The phosphorylation of p47phox increases 
its ability to assemble with p67phox forming a trimeric cytosolic protein complex 
as well as causing a conformational change of p47phox allowing it to interact with 
membrane-bound p22phox. Thus, p47phox recruits the cytosolic subunits of NOX2 
to the membrane. Once the subunits of the oxidase have assembled at the 
membrane, NOX2 becomes functional and gains its ROS-generating capacity 
involving the ability to transfer one electron from NADPH in the cytosol to 
oxygen on the external side of the membrane generating superoxide as depicted 
in Figure 4 (136). NOX2 may be expressed in the membrane of phagosomes or 
lysosomes thus generating intraphagosomal or intralysosomal ROS, or on the 
plasma membrane to generate extracellular ROS. 
 
 
Figure 4. NOX2 activation and ROS production. Upon assembly of the membrane bound and 
cytosolic subunits, NOX2 becomes active and capable of ROS formation. 
THE DUAL ROLE OF ROS IN CANCER 
ROS have been proposed to affect the initiation and progression of cancer on 
multiple levels. The arguably most established mechanism is that ROS may 
damage DNA with ensuing mutations and risk of cancer initiation (137-140). ROS 
have also been proposed to impact on established cancer cells by modulating the 
function of protein phosphatases (PTPs) and protein kinase C (PKC) through 
oxidation. PTPs and PKC are enzymes involved in post-translational 
modification of proteins. In an oxidized form, PTPs become inactivated whereas 
oxidation of PKC renders it active. ROS have been ascribed a role in increasing 
survival and preventing apoptosis of pancreatic cancer cells (141-143) and non-
small cell lung cancer cells (144, 145) through regulating PTPs. Increased ROS 
levels in these cells resulted in inactivation of PTPs with a resulting sustained 
activity of Janus kinase 2 (JAK2). Active JAK2 leads to phosphorylation of signal 
transducer and activators (STATs) resulting in activated transcription of anti-
apoptotic proteins (143). ROS may also influence the tissue-invasive properties 
of cancer cells by modulating the activity of mitogen-activated protein kinase via 
oxidation of PTPs and PKC (146-148). Moreover, NOX-derived ROS have also 
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been linked to a sustained cytoskeleton (149), increased proliferation, and 
prevented apoptosis of endothelial cells which are crucial features for successful 
angiogenesis (149, 150). ROS have additionally been implicated in signaling of the 
powerful pro-angiogenic factor, vascular endothelial growth factor (VEGF) (151-
153).  
 
The purported role of ROS in tumorigenesis and cancer progression has inspired 
the evaluation of antioxidant strategies for cancer prevention. These strategies 
include antioxidant diets (154, 155) and the administration of ROS scavengers 
(156). Whereas some of these studies support that certain antioxidants may reduce 
the risk of cancer development (154-156), there are also opposing results. In a 
Finnish trial, approximately 30,000 male smokers between 50 and 69 years were 
randomized to receive alpha-tocopherol, beta-carotene, a combination of alpha-
tocopherol and beta-carotene, or placebo. At five-year follow-up, the 
administration of beta-carotene was associated with a significantly higher 
incidence of lung cancer (157). Similar results were obtained in the CARET study 
that was prematurely stopped due to an increased incidence of lung cancer in 
participants supplemented with beta-carotene and alpha-tocopherol (158).  
 
While the reason for these partly contradictory results is incompletely understood, 
it is reasonable to assume that the pleiotropic actions of ROS may preclude a 
meaningful assessment of the clinical impact of systemic antioxidant 
supplementation. It is thus likely that the evaluation of ROS-modulating therapies 
in cancer should take the type of tumor, the phase of tumor development, the 
immune mechanisms that are relevant in controlling a specific tumor, the method 
of ROS modulation and, in particular, the source of ROS into account.  
ROS IN MYELOID LEUKEMIAS 
Genetic abnormalities including BCR-ABL1, FLT3-ITD, NRAS/BCL2 that are 
commonly observed in AML, CML, and myelodysplastic syndromes have been 
associated with enhanced cellular levels of ROS, as well as with accumulated DNA 
damage (138, 159, 160). As discussed above, increased ROS levels in malignant 
cells have been suggested to contribute to malignant cell proliferation, survival, 
genomic instability, and migration implying that oxidative stress in transformed 
cells may promote disease progression. 
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ROS IN AML 
One of the most common genetic alterations observed in AML is the FLT3-ITD 
mutation where FLT3 is constitutively active in leukemic cells with resulting 
downstream signaling involving the activation of STAT5. Cells transfected with 
FLT3-ITD and primary AML cells carrying FLT3-ITD show increased ROS 
levels that appear to be regulated through STAT5 signaling and Rac1 activation 
providing a possible mechanism for ROS generation. Using FLT3-ITD inhibitors 
it was shown that the induction of ROS was inhibited once signaling downstream 
FLT3-ITD was neutralized (159). It was suggested that the distinctively poor 
prognosis of patients with FLT3-ITD+ AML may be a result of FLT3-ITD-
induced ROS levels with a resulting genomic instability that drives the emergence 
of additional genetic alterations.  
 
It has additionally been suggested that AML cells may hijack and take advantage 
of ROS-regulated signaling pathways. NOX2-derived ROS have thus been 
proposed to provide pro-survival stimuli in the M07e AML cell line (161). The 
survival of primary AML cells also reportedly relies on NOX2-derived superoxide 
that facilitates energy transfer from BM stromal cells to the leukemic cells (162). 
There are however also conflicting reports suggesting that the induction of ROS 
triggers differentiation of AML cells (163). 
 
Monocytic AML cells have additionally been shown to produce 
immunosuppressive NOX2-derived extracellular ROS that trigger dysfunction in 
adjacent lymphocytes, a feature shared with healthy monocytes. The NOX2 
inhibitor HDC has been shown to protect NK cells from this mechanism of 
leukemia-induced immunosuppression, which may contribute to the clinical 
benefited of HDC-based therapy for relapse prevention in AML (37, 164). 
Moreover we present results in paper III implying that the inhibition of NOX2-
derived ROS, using HDC, stimulates the maturation of AML cells. Neutralization 
of ROS may thus target several aspects of pro-tumorigenic events orchestrated 
by ROS such as triggering the differentiation of AML cells, disrupting pro-
survival signaling pathways, reducing the genomic instability believed to promote 
disease progression, and facilitating immune-mediated clearance of leukemic cells.  
ROS IN CML 
ROS have been implicated in the progression of CML from chronic phase 
through accelerated phase to blast crisis by increasing the genomic instability in 
the leukemic cells with a resulting increase in the mutational rate. In support of 
this assumption, presence of the BCR-ABL1 translocation is associated with 
enhanced ROS levels in mature and immature cells (137, 138, 165). The degree of 
oxidative stress further increases during the accelerated phase and may predict 
disease progression (166). Disease progression is also associated with a depletion 
of non-enzymatic antioxidants that may further contribute to elevated ROS levels 
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(167). Diminished activity of glutathione S-transferase S, an enzyme involved in 
the protection against DNA oxidation, is associated with increased risk of 
developing CML at an early age and a reduced responsiveness to TKI therapy 
(168). In agreement with these reports, the results of paper IV imply that murine 
Nox2-deficient BCR-ABL1+ cells caused a less severe leukemia upon 
transplantation to mice as compared to Nox2-sufficient counterparts.  
 
In further support for oxidative stress as contributor to the genomic instability 
observed in CML, CD34+ cells transduced to express BCR-ABL1+ reportedly 
display approximately three to eight times more oxidized nucleobases compared 
with non-transformed cells (169). The ROS-induced DNA mutations encoded 
clinically relevant amino acid substitutes known to cause imatinib resistance. Also, 
treatment with ROS scavengers such as N-acetyl-L-cysteine (NAC) and vitamin 
E was found to decrease the mutagenesis rate and the frequency of imatinib 
resistance in transformed cells (165). Similar results were observed in a murine 
model of chronic phase CML where ROS-induced DNA damage in leukemic 
stem cells caused TKI-resistant mutations such as the gatekeeper mutation T315I 
(137). Furthermore, despite TKI therapy the enhanced ROS levels in the leukemic 
stem and progenitor cells remain elevated (137, 170-172). Thus, ROS may 
contribute to the genomic instability observed in CML cells and to TKI resistance. 
Treatment with the antioxidant NAC in conjunction with TKI have additionally 
also been shown to render BCR-ABL1+ cells more vulnerable to TKI therapy by 
promoting TKI-induced apoptosis suggesting that the enhanced ROS levels may 
also make the cells less sensitive to the therapy (173).  
 
Treatment discontinuation of TKI therapy has been evaluated in patients in deep 
molecular remission. An interim analysis of the European Stop Tyrosine Kinase 
Inhibitor Study revealed that 53 % of patients who had been treated with TKIs 
for < 8 years and 74 % of patients treated with TKIs for > 8 years remained in 
treatment-free remission six months after TKI cessation (174). The results also 
showed that patients who remained in remission had significantly higher counts 
of NK cell with cytotoxic phenotype at enrolment compared with patients 
experiencing leukemic relapse (175). The authors concluded that cytotoxic NK 
cells may be of value for successful TKI discontinuation. Human and murine 
BCR-ABL1+ CML cells reportedly express functional NOX2 (176, 177) and 
produce NOX2-derived immunosuppressive ROS (176). Hence, it may be 
speculated that the targeting of NOX2-derived ROS, produced by the leukemic 
cells, may protect NK cells from ROS-induced dysfunction in CML.  
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TUMOR MICROENVIRONMENT 
The TME is a complex environment comprised not only of malignant cells but 
also of stromal cells, cancer-associated fibroblasts, lymphocytes, and epithelial 
cells lining the tumor vasculature. The tumor-infiltrating cells as well as the 
extracellular matrix that embed the tumor and the physiological condition within 
the tumor mass, such as oxygen supply and acidification, are factors orchestrated 
by the malignant cells that will influence tumor progression.  
NEOVASCULARIZATION AND ACIDIFICATION OF THE TME 
The oxygen tension in the TME is typically reduced resulting in a state of chronic 
hypoxia, which is likely explained by the enhanced proliferation of malignant cells 
resulting in shortage of nutrients and oxygen. The hypoxic environment 
stimulates the malignant cells to secrete factors such as VEGF that triggers 
branching of preexisting vessels to initiate the formation of new vessels (178). 
The quickly increasing demand of vasculature by the growing tumor results in the 
generation of dysfunctional vessels with a fluctuating blood flow and intermittent 
oxygen availability, which is referred to as cycling hypoxia (179-181). Chronic and 
cycling hypoxia exert effects on the TME, many of which are mediated via the 
transcription family of hypoxia-inducible factors (HIFs) (178, 182). Hence, HIFs 
are the main mediators of cellular adaptation to hypoxia. In normoxic tissues, 
oxygen sensors, such as propyl hydroxylases, will induce the degradation of one 
of the HIF subunits, HIF-D, by the proteasome. In hypoxic environments the 
oxygen sensors lose the ability to induce HIF-D degradation and as a consequence 
it will translocate to the nucleus where it dimerizes with HIF-E subunits to initiate 
the transcription of HIF-target genes (178, 183). In this manner, the activation of 
HIF by hypoxia influences cancer by i) promoting tumor growth by inducing 
neovascularization via VEGF (184), ii) increasing cell survival via growth factors 
and inhibition of proapoptotic pathways (185), iii) contributing to metastasis by 
modulating cell adhesion molecules and mobility through the regulation of 
epithelial-to-mesenchymal transition (186, 187), and iv) conferring resistance to 
chemotherapy by inducing quiescence of malignant cells (178). Hypoxia also 
regulates several signaling pathways, enhances ROS generation, and inhibits 
homologous recombination and mismatch repair, thus increasing genomic 
instability (178). The expression of HIF-D in primary tumors and metastasis is 
associated with adverse prognosis and more aggressive diseases (188). Despite 
these observations, the anti-neoplastic efficacy of HIF inhibitors in humans 
remains to be established.  
 
The malignant transformation of a cell typically involves a metabolic 
reprogramming from oxidative phosphorylation to aerobic glycolysis. The 
hypoxic milieu in the TME favors anaerobic glycolysis over aerobic energy 
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metabolism leading to the generation of lactic acid and acidification of the 
surrounding tissue (189). The generation of lactate inhibits the ubiquitination and 
the proteasomal degradation of HIF-D and hence the acidification and the 
hypoxia promote one another (190). The resulting acidification of the TME 
influences on various tumor-infiltrating cells and may results in 
immunosuppression. A reduced pH has thus been shown to diminish the 
cytotoxicity of both CD8+ T cells (191) and NK cells (192). In addition to 
suppressing cytotoxic lymphocytes with anti-tumor functions, the acidification 
recruits myeloid cells that may differentiate into immunosuppressive myeloid-
derived suppressor cells (192) or M2-like tumor-associated macrophages (TAMs) 
(193). HIF-1D activation has also been shown to enhance the expression of the 
Treg specific transcription factor forkhead box P3 (194).  
TUMOR INFILTRATING IMMUNE CELLS 
The presence of DCs, T cells, and NK cells within or adjacent to tumors is 
associated with favorable outcomes in several forms of cancer (195). However, 
immune activation within the tumor may result in the development of chronic 
inflammation that promotes exhaustion of the tumor-infiltrating lymphocytes 
(TILs) and the recruitment of immunosuppressive immune cells, such as myeloid-
derived suppressor cells, TAMs, and Tregs (196, 197). Together with the acidic and 
hypoxic conditions already manifested in the TME the milieu may rapidly shift 
into a hostile environment for anti-tumor immune cells with ensuing immune 
escape.  
NEUTROPHILS AND MONOCYTES IN CANCER – MYELOID-
DERIVED SUPPRESSOR CELLS 
Patients with cancer often present with elevated numbers of a heterogeneous 
population of immature myeloid cells (IMCs) in peripheral tissues and in the 
TME. While IMCs likely exert multiple functions, they have been shown to 
efficiently suppress functions of cytotoxic lymphocytes (38, 198-202). Initially, the 
IMCs were characterized based on their lack of expression of markers for B cells, 
T cells, NK cells, and macrophages. There was however no consensus regarding 
the nomenclature and the cells have during the years been referred to as IMCs, 
myeloid suppressor cells, and GR1+ cells since GR1 distinguishes these cells in 
mice. In 2007, Gabrilovich and co-workers proposed the term myeloid-derived 
suppressor cells (MDSCs) to encompass myeloid cells that dampen cellular 
immunity and the term have since been used to refer to this heterogenous 
population of cells (203). Cells with a phenotype similar to MDSCs are generated 
also during acute inflammation, but under these circumstances the cells are 
generally not highly immunosuppressive, but rather contribute in tissue repair, in 
wound healing, and to homeostasis (204). 
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The chronic inflammation characteristic of the TME triggers myelopoiesis and 
consequently IMCs are released from the BM and accumulate in the periphery 
and in the TME. Tumor cell-derived cytokines, such as GM-CSF and IL-6, 
promote the expansion of IMCs (205-210) while factors secreted by tumor 
stromal cells and activated T cells, including IFN-J, ligands for TLRs, IL-4, IL-
13, and TGF-E, induce the activation of IMCs into MDSCs (204, 211-213). Hence 
the generation of MDSCs is sometimes referred to as a “two-signal model” and 
illustrates that tumors may highjack preexisting biological mechanisms to recruit 
cells that promote their progression. The generation of MDSCs in cancer is 
depicted in Figure 5. 
 
 
Figure 5. Myeloid differentiation in health and in cancer. In healthy individuals, IMCs rapidly 
differentiate into mature myeloid cells upon migration from the BM to the periphery. Cancer 
patients often present with impaired myeloid differentiation where IMCs accumulate in the 
periphery in response to tumor-derived growth factors. Additional factors mainly produced by 
activated T cells and stromal cells in the TME, activate IMCs to become MDSCs that are divided 
into granulocytic- or monocytic MDSCs (G- and M-MDSCs, respectively). 
MDSCs are currently acknowledged as key players in immunosuppression and 
immune escape in cancer and positively correlate with the tumor burden and the 
stage of disease (214-217). In addition, there is a negative correlation between 
MDSCs and immune responses in cancer therapy (218) and the targeting of 
MDSCs in mice have been shown to improve immune responses and to reduce 
tumor growth rate (219, 220). A compelling body of evidence hence suggests that 
the accumulation of MDSCs in cancer is a disadvantageous event and a possible 
therapeutic target.  
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Characteristics of MDSCs 
MDSCs are not a unique subset of cells but a population of immunosuppressive 
cells that differ in morphology, phenotype, and suppressive effector functions. 
These cells are often divided into monocytic- and granulocytic-MDSCs (M- and 
G- or PMN-MDSCs, respectively, Figure 6). In mice the phenotypic identification 
of MDSCs, M-, and G-MDSCs is relatively straightforward. Murine MDSCs are 
characterized by their expression of CD11b and GR1. The expression level of the 
GR1 epitopes Ly6C and Ly6G is employed to distinguish M-MDSCs from G-
MDSCs, where M-MDSCs are CD11b+GR1+Ly6ChighLy6G- and the G-MDSCs 
are CD11b+GR1+Ly6ClowLy6G+. No human marker corresponding to GR1 in 
mice has been identified and hence the phenotype of human MDSCs is under 
debate. However, the currently most used definition of human M-MDSCs is 
CD33+CD11b+CD14+HLA-DRlow cells whereas G-MDSCs are defined as 
CD33+CD11b+CD15+CD66b+HLA-DR- cells. In addition, the G-MDSCs are 
found in the peripheral blood mononuclear cell fraction upon density gradient 
centrifugation in contrast to neutrophils that are pelleted out over Ficoll-Paque 
(221, 222). G-MDSCs are, similarly to normal neutrophils, sensitive to 
cryopreservation and can therefore mainly be studied using fresh samples. Hence, 
many clinical studies are restricted to examining the impact of M-MDSCs for, e.g., 
the course of disease. The phenotypic definition of MDSCs is however not 
sufficient to classify a cell as a MDSC, as an additional requirement is that the cell 
is capable of immunosuppression. The characterization of MDSCs hence involves 
phenotypical as well as functional assessment.  
 
 
Figure 6. G- and M-MDSCs. MDSCs are categorized as G- or M-MDSCs. G-MDSCs may further 
differentiate into M-MDSCs that in turn may be triggered to differentiate into monocytes or DCs. 
MDSCs express NOX2 and iNOS by which they generate immunosuppressive ROS and NO 
triggering dysfunction in adjacent lymphocytes. 
ROS
NO
NOX2
iNOS
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Expansion and activation of MDSCs 
Cytokines like GM-CSF and IL-6 drive the expansion of MDSCs via stimulating 
phosphorylation of the transcription factor STAT3 in myeloid cells. The 
activation of STAT3 in IMCs has been shown to increase the survival and 
proliferation of myeloid cells and to block their differentiation with ensuing 
expansion of incompletely differentiated myeloid cells with characteristics similar 
to those of MDSCs (211). Support for a role of STAT3 in the expansion of 
MDSCs is also provided by studies reporting that MDSCs from tumor-bearing 
mice show upregulated expression of STAT3 (223) and that Stat3-deficeint mice 
show reduced expansion of MDSCs (224).  
 
The activation of MDSCs is mainly dependent on STAT1 and STAT6 (211). IFN-
J, IL-4, and IL-13 are assumed to be involved in triggering the activation of 
STAT1 and STAT6, inducing the generation of MDSCs. Signaling via the IFN-J 
receptor or the IL-4 receptor D results in downstream activation of STAT1 and 
STAT6, respectively, following upregulation of arginase 1 and iNOS, which are 
two of the main immunosuppressive mechanisms utilized by MDSCs (225, 226). 
The STAT1-involvement in MDSC activation is supported by results showing 
that Stat1 knockout mice are incapable of arginase 1 and iNOS upregulation and 
do not inhibit T cell responses (227).  
Main suppressive mechanisms of MDSCs 
Arginase 1 and iNOS 
L-arginine is essential for proper function of effector T cells and thus crucial for 
anti-tumor T cell responses. Shortage of L-arginine in the microenvironment 
results in T cell dysfunction because of reduced expression of the CD3ζ-chain 
and reduced T cell proliferation. MDSCs have been shown to express the two 
enzymes arginase 1 and iNOS that uses L-arginine as a substrate (211, 228). 
Arginase 1 converts L-arginine into urea and L-ornithine whereas iNOS uses L-
arginine in the generation of NO and L-cirtrulline (229). Because of the high 
enzymatic activity of arginase 1 and iNOS by intratumoral MDSCs, L-arginine is 
depleted from the TME resulting in dysfunctional tumor-infiltrating T cells. In 
addition, NO exerts immunosuppression by inhibiting JAK3 and STAT5 
signaling in T cells and by preventing MHC class II expression (230, 231).     
ROS 
Similar to normal phagocytes, MDSCs express the myeloid ROS-generating 
enzyme NOX2. STAT3, which is activated during cancer, is ascribed responsible 
for the enhanced NOX2-derived ROS-generating properties of MDSCs (213). 
Myeloid cells from Nox2 knockout mice fail to upregulate ROS production during 
tumor growth supporting that the increased ROS formation observed by MDSCs 
is dependent on a functional NOX2 (232). The importance of NOX2-derived 
ROS as a promotor of tumor growth is somewhat controversial. In certain 
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experimental tumor models of melanoma and Lewis lung carcinoma there is a 
reduced tumor growth in Nox2-deficient mice (220, 233). In contrast, Nox2 
knockout mice do not show reduced sensitivity to sarcoma, lymphoma, and 
prostate cancer growth (232-235).  
 
While the importance of NOX2 for solid tumor growth may vary, NOX2-derived 
ROS may have a greater impact on promoting metastasis formation. Hence, 
intravenously injection of B16-F10 melanoma cells or mouse mammary cancer 
cells consistently gave rise to less metastases in mice lacking NOX2 (220, 236). 
Furthermore, in a study by Okada et al, no difference on primary tumor growth 
was observed between wild type and Nox2 knockout mice for two murine cancer 
cell lines, whereas Nox2 knockout mice exhibited reduced spontaneous metastasis 
formation with fewer metastatic nodules in both models. The effect was linked to 
NOX2-derived ROS-induced expression of Thymosin E4 that enhanced the 
motility of the tumor cells (237). 
 
Extracellular release of NOX2-derived ROS may trigger dysfunction and 
apoptosis in adjacent T cells and NK cells (38, 235, 238, 239). MDSC-derived 
ROS have also been shown to inhibit antigen-specific CD8+ T cell responses 
(235). The effect has been linked to nitration of the TCR that was found to occur 
when ROS reacted with NO to form peroxynitrite during direct MDSC-T cell 
interactions. It has been proposed that nitration of the TCR results in a 
conformational change of the receptor resulting in less efficient interaction with 
and killing of tumor cells presenting the cognate peptide (240). Myeloid cell-
derived ROS purportedly also impedes the effector function of NK cells (38). In 
accordance with these findings, genetic and pharmacological disruption of NOX2 
resulted in reduced tumor growth in a murine model of metastatic melanoma. 
The effects of NOX2 inhibition were lost upon depletion of GR1+ cells or NK 
cells, thus implying that NOX2-mediated NK cell suppression may affect 
metastasis (220). 
 
Upregulation of NOX2 further seems to be important for proper generation of 
MDSCs since both tumor-bearing Stat3 and Nox2 knockout mice present with a 
more mature myeloid population and fewer MDSCs than wild type mice (232, 
241). These results are coherent with the observed effect of ATRA, which has 
been shown to upregulate the levels of the antioxidant enzyme glutathione 
synthase with a subsequent neutralization of ROS with ensuing differentiation of 
MDSCs and DCs from breast cancer, colorectal cancer, and renal cell carcinoma 
patients (242-245). ATRA was further shown to target MDSCs in murine tumor 
models as well as in patients with metastatic renal cell carcinoma (246, 247). The 
role of ROS as inhibitor of maturation is further supported by results suggesting 
that the antioxidant NAC triggers differentiation of MDSCs (248). 
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Further, albeit indirect, support that the increased ROS levels in MDSCs are of 
relevance to maintain an immature phenotype of MDSCs stems from experiments 
performed in histidine decarboxylase-deficient mice. Histidine decarboxylase is 
highly expressed by myeloid cells and MDSCs and is responsible for the synthesis 
of histamine, a known NOX2 inhibitor. Histidine decarboxylase-deficient mice 
show an increased susceptibility to colon and skin cancer and reduced growth of 
glioma. Tumor-bearing histidine decarboxylase-deficient mice presented with 
increased amounts of MDSCs along with diminished CD8+ T cells effector 
functions (249, 250). Exogenous administration of histamine to histidine 
decarboxylase-deficient tumor-bearing mice induced maturation of myeloid cells 
and suppressed the growth of tumor allografts (249). MDSCs from tumor-bearing 
mice additionally showed reduced histidine decarboxylase activity compared with 
cells isolated from non-tumor-bearing mice and an inverse correlation between 
histidine decarboxylase activity and the immunosuppressive properties of MDSCs 
was also observed (250). The potential importance of histamine in cancer 
prevention is also highlighted by epidemiological studies suggesting that allergens, 
likely driving the endogenous production of histamine, may be protective against 
glioma and leukemia (251, 252). An inverse correlation between risk of cancer 
development and atopy has been reported for colorectal cancer and childhood 
leukemia whereas studies in other malignancies did not show this association 
(253). While further studies are needed in this area, the results are compatible with 
the view that presence of an endogenous NOX2 inhibitor (histamine) in tissues 
may control tumor growth by targeting MDSCs, which is supported by our 
findings in paper I, paper II, and paper III suggesting a pro-differentiating 
effect of HDC on myeloid cells.  
MACROPHAGES IN CANCER 
Macrophages, similar to MDSCs, frequently accumulate in the TME during tumor 
progression (tumor-associated macrophages, TAMs) (254). CCL2 have been 
shown to promote the recruitment of monocytes to the tumor area whereas 
cytokines that are present in the TME, such as IL-4, IL-10, and IL-13, may induce 
the differentiation of monocytes into M2-like macrophages (254-257). M2 TAMs 
are assumed to promote tumor progression and may herald adverse prognosis in 
cancer (258). M1 macrophages may instead kill tumor cells by releasing NO and 
by producing TNF (259). Redirection of M2 macrophages into M1 macrophages 
by in vivo administration of anti-IL-10 has been shown to synergize with CCL16 
and TLR stimulation to promote tumor rejection (257). The subdivision of TAMs 
into the M1 and M2 phenotypes is however challenged by reports describing 
multiple TAM phenotypes and TAMs presenting with M1 as well as M2 
characteristics (260, 261). 
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DENDRITIC CELLS IN CANCER 
The mobilization of a robust anti-tumor immune response is dependent on the 
activation of cDCs. Studies in murine models imply that the primary function of 
cDCs in cancer is to endocytose dead neoplastic cells or cellular debris and 
process and present the associated tumor antigens to T cells (262, 263). The ability 
of the cDC1s to cross-present tumor antigens is essential for activation of anti-
tumor cytotoxic T cells as suggested, for example, by the finding that Batf3-
deficient mice, which do not generate cDC1s, cannot reject highly immunogenic 
cancer cells. In addition, these mice are poor responders to immunotherapy with 
programmed cell death protein 1 (PD-1) neutralizing antibodies (264, 265).  
 
Several studies support that DCs are dysfunctional in cancer patients, which may 
partly explain the state of immunosuppression characteristic of many cancer 
forms (266, 267). DCs from cancer patients accordingly express reduced levels of 
costimulatory molecules such as CD80 and CD86 (268). In addition, tumor cells 
may promote the maturation of DCs to express OX40 ligand favoring the 
development of TH2 immune responses. These cells secrete IL-4 and IL-13 that 
may prevent tumor cell apoptosis and stimulate immunosuppressive TAMs. 
Presence of intratumoral TH2 cells has been reported to promote breast cancer 
growth and also correlate with adverse prognosis in patients with pancreatic 
cancer (269, 270). Numerous strategies, including DC vaccines and the 
administration of cytokines known to stimulate DCs such as GM-CSF, have been 
proposed to boost cellular immunity in cancer (262, 268).  
T CELLS IN CANCER 
MHC class I-mediated recognition of malignant cells requires that the MHC class 
I-presented peptide on the tumor cell is a tumor antigen. There are two major 
forms of tumor antigens, tumor-associated antigens and tumor-specific antigens. 
The tumor-specific antigens are expressed solely by the malignant cells and 
originate from mutated proteins. The tumor-associated antigens instead arise 
from an altered expression profile of the transformed cells resulting in increased 
expression of proteins that normally are dimly expressed or only expressed in 
specific tissues (271). The tumor-associated antigens include cancer-germline 
genes, differentiation antigens, overexpressed antigens, and viral antigens. 
 
Depending on the mutational burden, a tumor may be more or less immunogenic 
since tumors expressing a high number of neoantigens are likely to present more 
mutated peptides that may be recognized by T cells. Melanoma is associated with 
a high mutational frequency whereas patients with AML typically present with 
fewer non-synonymous mutations (272). The importance of the number of 
mutations for the ability of the immune system to evoke an anti-tumor immune 
response is underlined by results suggesting that there is a positive correlation 
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between the clinical efficacy of checkpoint inhibitors in cancer and the tumor 
mutational burden (273). 
 
The importance of T cell-mediated anti-tumor immunity in cancer is highlighted 
by results obtained in, inter alia, melanoma (274), non-small cell lung cancer (275), 
breast cancer (276, 277), and ovarian cancer (278) showing that infiltration of 
tumors with anti-tumor T cells heralds favorable prognoses. In addition, it has 
been reported that a high CD8+ T cell to Treg ratio is associated with a more 
favorable clinical outcome in cancer, thus suggesting that Tregs may negatively 
impact on the cytotoxic function of CD8+ T cells (278-280). Many efforts to boost 
T cell immunity in cancer have focused on triggering CD8+ T cell responses, but 
CD4+ TH1 cells are also endowed with anti-tumor effector functions, in particular 
by providing help during the priming of CD8+ T cells. Studies in mice show that 
depletion of CD4+ T cells reduces the efficacy of tumor vaccines and 
immunotherapy using IL-7 (281, 282). A protective role of TH1 CD4+ T cells in 
anti-tumor defense was further supported by experiments using adoptive transfer 
of melanoma-reactive TH1 CD4+ T cells to tumor-bearing mice (283, 284). 
T cell exhaustion in cancer 
T cell-mediated immune responses in cancer follow the same biological traits as 
those observed during infections with viruses or intracellular bacteria. Since these 
pathways are likely evolutionary developed mainly to combat acute infections 
various immunosuppressive mechanisms eventually evolve to prevent prolonged 
immune effector function and autoimmunity and to aid in wound healing and 
restoration of tissue homeostasis (285). Consequently, tumor-infiltrating T cells 
are often subjected to exhaustion. Complete elimination of a tumor would 
however likely require extended immunity. 
 
The immunosuppressive environment in the TME, including hypoxia, 
neovascularization, and immunosuppressive cells such as MDSCs and TAMs, has 
been discussed in previous sections but additional mechanisms are of relevance 
to T cell dysfunction and exhaustion. One intrinsic driver of T cell exhaustion is 
the persistent exposure to cognate antigen in the TME resulting in upregulated 
expression of immune checkpoint inhibitors on T cells (286, 287). The expression 
of PD-1 on T cells with a concomitant expression of programmed death-ligand 1 
or 2 (PD-L1/L2) in the TME has emerged as a critical aspect of cancer-related T 
cell dysfunction. PD-1 expression on tumor-infiltrating T cells is thus considered 
a hallmark of T cells with reduced effector functions and is often associated with 
the expression of additional checkpoints. These include lymphocyte-activation 
gene 3 (LAG3), CTLA-4, T cell immunoglobulin and mucin domain-2 protein, 
along with T cell immunoglobulin and ITIM domain that all contribute in 
reducing T cell effector functions (286-288). The importance of checkpoints in 
controlling T cell functions is underscored by the clinical success of using PD-1, 
PD-L1, and CTLA-4 neutralizing antibodies in cancer immunotherapy (289-292).  
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The T cells propagating the TME are not only CD8+ and TH1 CD4+ T cells. 
Regulatory T cells, inhibiting immune responses, may represent a substantial part 
of the CD4+ T cell pool within the TME. In mouse models, the depletion of Tregs 
has been shown to improve anti-tumor immunity (293). While the detailed 
mechanisms involved remain to be defined, Tregs are known to reduce the 
expression of costimulatory molecules by APCs (116) and to produce 
immunosuppressive cytokines including TNF-E and IL-10 resulting in impaired 
T cell activation, survival, and expansion (285).  
NK CELLS IN CANCER 
Animal models have revealed that depletion of NK cells or transplantation of 
tumor cells into NK cell-deficient mice results in elevated tumor growth and, in 
particular, increased formation of metastases (220, 294-296). Similar results were 
obtained when mice lacking NK cell effector molecules such as perforin or IFN-
J were challenged with tumor cells (220, 297). In humans the infiltration of NK 
cells into solid tumors is mostly modest but the presence of tumor-infiltrating NK 
cells may herald favorable prognosis (298-300). Additionally, patients harboring 
circulating NK cells with intermediate or high cytotoxic function showed reduce 
cancer risk in a 11-year-follow up study, which supports a role for NK cells in the 
early control of transformed cells (301).  
 
The killing of MHC class I-expressing transformed cells by cytotoxic T cells 
results in a selective pressure that favors the survival of malignant cells with 
reduced expression of MHC class I. The downregulation of MHC class I can be 
the result of mutations, deletions or hypermethylation in human leukocyte antigen 
(HLA)-genes, loss of heterozygosity in chromosome 6 or 15, or by transcriptional 
downregulation of HLA-related genes (302). The reduced expression of HLA 
molecules however renders the malignant cells more susceptible to NK cell 
cytotoxicity since NK cells are inhibited upon encountering cells expressing HLA 
class I molecules. Functions of NK cells against transformed cells are also 
promoted by the expression of stress ligands, including ULBPs and MHC class I 
chain related A and B (MICA and MICB, respectively), on tumor cells (303-305). 
It has also been reported that tumor cells express ligands for natural cytotoxicity 
receptors, such as ligands for NKp30 and NKp44, contributing to anti-tumor NK 
cell activity (306, 307). 
 
NK cells are considered to be less efficacious in controlling established solid 
tumors than in the control of early malignant cells, possibly as a consequence of 
NK cell immune escape. The suppressive microenvironment in the TME, 
including the presence of immunosuppressive cells and cytokines, has been 
suggested to diminish NK cell-mediated immunity through reduced expression 
of NK cell activating receptors (308, 309). Additionally, tumor cells may shed and 
 33 
release soluble MIC ligands that bind to NKG2D with ensuing inhibition of NK 
cell function (310).  
 
NK cells however appear to play a critical role in the control of hematological 
malignancies. One can speculate that the importance of NK cells in hematological 
malignancies stems from a less immunosuppressive environment compared with 
that observed within solid tumors. On the other hand malignant blasts reportedly 
frequently express HLA class I molecules to inhibit NK cell cytotoxicity via 
ligating inhibitory KIRs on NK cells (311). The importance of KIR signaling is 
highlighted by results showing that the NK cell cytotoxicity against malignant 
myeloid cells is enhanced when there is a KIR-ligand mismatch between NK cells 
and target cell in vitro (312). In further support of the importance of inhibitory 
KIR-signaling for NK cell cytotoxicity, infusion of donor NK cells with a 
mismatched HLA-KIR profile between donor and recipient has been suggested 
to be protective against leukemic relapse in AML and myelodysplastic syndrome 
compared with a matched regimen (313-315). These results imply that antibodies 
neutralizing KIR-signaling, blocking the engagement of inhibitory KIRs with 
cognate ligands, may have a clinical value analogous to checkpoint inhibitors 
designed to target T cell dysfunction. One such antibody, IPH2101 that targets 
KIR2D, has been evaluated and shown efficacy in preclinical models of multiple 
myeloma and lymphoma (316-318). In addition, AML patients with NK cells at 
early stages of maturation show a poorer clinical outcome than those harboring 
mature and functional NK cells (319). The expression of natural cytotoxicity 
receptors also influences on the prognosis of AML as patients with a low 
expression of NKp30 and NKp46 at diagnosis display reduced survival rates 
(320).   
 
Remission maintenance therapy with HDC and low-dose IL-2 has been shown to 
reduce the risk of relapse in the post-chemotherapy phase of AML (37, 39, 321). 
Serial analyses of the immune phenotype of patients undergoing HDC/IL-2 
therapy have revealed that the NK cell repertoire of a patient impacts on outcome 
where, among other factors, expression of the NK cell-activating receptors 
NKp46 and NKp30 is associated with favorable prognosis (164, 322, 323). These 
results thus provide additional support for the relevance of NK cell function in 
determining the outcome of leukemia.     
 
As in AML, dysfunctional NK cells are found in human CML before and on TKI 
treatment as well as in mice carrying BCR-ABL1+ cells (324). In addition, it has 
been reported that the number of NK cells in patients with CML gradually 
decreases as patients progress from chronic to accelerated phase (325). Patients 
with CML present with granulocytic BCR-ABL1+ CML cells with characteristics 
of MDSCs which are endowed with potent immunosuppressive features (176, 
326-328). The presence of M-MDSC-like cells has also been observed in CML 
patients (329) and the levels of both G- and M-MDSCs are reportedly elevated in 
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patients at the time of diagnosis (327, 329). However, it remains uncertain 
whether TKI treatment restores the MDSC-levels to that of healthy controls (326, 
327, 329). It may thus be speculated that a remaining pool of MDSCs sustained 
in a fraction of patients also after treatment with TKIs may explain the 
quantitative and functional NK cell defects observed in CML. As discussed in 
detail previsouly, recent results imply that the NK cell status in CML influences 
the likelihood of successful TKI discontinuation (330). Means to restore the 
functionality of NK cells, possibly through targeting the remaining pool of 
MDSCs, is thus a conceivable strategy to improve the likelihood of sustained 
leukemia-free survival after cessation of TKIs. 
B CELLS IN CANCER 
Certain B cells are capable of producing autoantibodies that are directed against 
self-antigens and hence may cause autoimmune diseases. Despite that the 
formation of autoantibodies is considered an undesired event, autoantibodies 
with specificity for neoplastic cells, “tumor-associated autoantibodies”, may 
participate in controlling malignant growth and may also be useful as diagnostic 
markers. While understanding the role of B cells in cancer requires further study, 
it has been proposed that B cells may mount and modulate pro- as well as anti-
tumor innate and T cell responses within the TME (331, 332). 
IMMUNOTHERAPIES 
Cancer immunotherapy, aiming at inducing or reinforcing immune responses 
against malignant cells, has emerged as a viable cancer treatment. The prototypic 
immunotherapy is allogeneic bone marrow transplantation (allo-BMT), which is 
commonly used in leukemia and lymphoma, where the hematopoietic cells of a 
patient are replaced by cells from a matched donor aiming at achieving a graft-
versus-leukemia reaction to eliminate malignant cells. For example, allo-BMT is 
practiced in younger patients with intermediate- or high-risk AML (29). The lack 
of matched donors, the age barrier, the treatment-related mortality and morbidity 
along with the lack of clinical benefit of allo-BMT in most forms of solid cancer 
has inspired the development of alternative strategies aiming at ameliorating 
tumor immunity. 
 
The early development in this area was focused on the activation of cytotoxic 
lymphocytes and included the administration of IFN-D (333, 334), a pleiotropic 
NK cell-activating cytokine, and IL-2 that promotes NK and T cell cytotoxicity 
and proliferation (335-337). Both of these compounds have been used clinically, 
mainly in metastatic melanoma and metastatic renal cell carcinoma. In AML, the 
only cytokine-based therapy that has proven clinically efficacious in a controlled 
phase III trial is HDC/IL-2 that reduces the risk of leukemic relapse in the post-
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chemotherapy phase of AML (37, 321). In recent years, “checkpoint inhibitors” 
have been successfully implemented in the treatment of patients with advanced 
or metastatic cancer. Checkpoint inhibitor therapy, which aims at countering T 
cell suppression in the TME, is currently approved in several forms of cancer and 
the list of cancers in which such therapy is significantly clinically beneficial is 
rapidly growing (338-340).   
IMMUNOSTIMULATORY CYTOKINES 
Cytokines are growth factors that allow for communication between immune cells 
to coordinate immune responses and are mainly produced by innate and adaptive 
immune cells. The outcome of an interaction between a cytokine receptor and a 
cytokine is determined by the local concentration of the cytokine, the expression 
profile of the cytokine receptor as well as what response a cytokine triggers in the 
affected cell (341). Cytokines may either be immune activating or 
immunosuppressive. Cytokine-based cancer therapies thus include strategies that 
inhibit immunosuppressive cytokines as well as the administration of immune-
activating cytokines. Immunosuppressive cytokines include IL-10 and TGF-E 
whereas IL-2, IL-15, and IFNs are examples of immune activating cytokines. 
However, cytokines are in general pleiotropic and may trigger dissimilar outcomes 
in different cells as exemplified by IL-2 that triggers the activation of the effector 
T cell compartment and the T regulatory compartment simultaneously, potentially 
leading to concomitant immune activation and inhibition (342). 
 
The importance of cytokines in the control of tumor cells is highlighted by the 
results of murine studies demonstrating that mice genetically deficient in IFN-J 
receptors or proteins essential for downstream IFN signaling more frequently 
develop spontaneous and chemically induced cancer (297, 343). It has further 
been shown that cytokines and lymphocytes collaborate to protect against the 
development of carcinogen-induced sarcomas and spontaneous epithelial 
carcinomas, but simultaneously select for tumor cells with reduced 
immunogenicity (343). In line with these murine studies, adjuvant IFN-D has been 
used in the treatment of stage III melanoma and was previously used as frontline 
therapy for CML whereas IL-2 has shown efficacy in the treatment of metastatic 
melanoma and renal cell carcinoma (333, 344-347).  
 
The response to IFN-D is likely multi-faceted involving enhanced expression of 
MHC class I on tumor cells and induction of DC maturation, as well as activation 
of T cell and NK cell effector functions (348-351). The mechanism of anti-tumor 
action of IFN-D is hence complex but its ability to induce MHC class I expression 
on melanoma cells has been forwarded as a pivotal aspect of efficacy. The 
hypothesis is bolstered by the clinical effectiveness of IFN-D in hairy cell leukemia 
where malignant cells carry mutations in the BRAF gene as also reported for 
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melanoma cells (352, 353). In melanoma, BRAF mutations reportedly result in 
reduced expression of tumor-associated antigens (354). A similar effect on BRAF-
mutated hairy cell leukemia cells would, in part, explain why two seemingly 
different disease respond to IFN-D therapy.  
  
IL-2 is predominantly produced by TH1 CD4+ T cells and stimulates the 
proliferation of NK cells and T cells along with efficiently boosting NK cell 
cytotoxicity. In 1984 a heavily pretreated female with metastatic melanoma 
achieved long-lasting CR in response to high-dose IL-2 demonstrating that T and 
NK cell stimulating therapies could result in complete eradication of advanced 
cancers (355). However, only < 10 % of patients with advanced melanoma or 
renal cell carcinoma achieve CR upon high-dose IL-2 therapy (356, 357). The 
effect of IL-2 on Tregs and its ability to trigger activation-induced immune cell 
death may dampen the antitumor immune functions (358). Thus, cytokines that 
selectively activate effector T cells and NK cells without inducing Tregs may show 
superior antitumor activity. The current development in this area comprises the 
evaluation of modified variants of IL-2 to reduce off-target immunosuppression 
and IL-15 that shares the immune activation achieved by IL-2 but with reduced 
Treg expansion (359-363).  
ADOPTIVE CELL THERAPY 
Adoptive cell therapy (ACT) refers to the infusion of in vitro-expanded 
lymphocytes. Allo-BMT is the most robust form of ACT and an effective 
therapeutic option in leukemias as previously discussed. For ACT in solid 
malignancies the lymphocytes, most often autologous T cells or NK cells, are 
usually isolated from peripheral blood, but occasionally also from tumor draining 
lymph nodes or tumor tissue. This strategy may circumvent potential inhibitory 
mechanisms manifested in the host such as immunosuppression and tolerance to 
tumor antigens. The isolated lymphocytes are cultured in a cocktail of growth 
factors aiming at expanding the antitumor immune cells and to reverse potential 
functional impairment. To increase the likelihood of sustained function and 
survival of the infused cells lymphodepletion often precedes infusion aiming at 
reducing immunosuppressive host populations such as MDSCs and Tregs. Patients 
receiving ACT also frequently receive cytokines to further support the viability 
and functionality of the infused cells (364).  
 
Although results of randomized comparisons that evaluate the clinical efficacy of 
ACT are not available, a lymphodepleting conditioning regimen in conjunction 
with the infusion of TILs together with supplementation of IL-2 has shown 
promising results in the treatment of metastatic (phase IV) melanoma (365, 366). 
ACT is however not widely used for the treatment of solid malignancies, partly 
due to the high technical requirements needed to establish a functional infusion 
product. Additionally, TIL therapy has shown limited clinical efficacy in solid 
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malignancies besides melanoma. The high mutational burden in melanoma, which 
is associated with the presence of multiple tumor antigens has been suggested to 
explain why melanoma patients may be more likely to respond to ACT compared 
with patients with other forms of cancer (364). A limiting factor of ACT in solid 
malignancies stems from a defective homing of the infused cells to the tumors. 
Means to improve lymphocyte infiltration to the tumor site have thus been 
evaluated aiming to improve the effectiveness of the therapy. The ex vivo 
expansion of human NK cells results in increased expression of the chemokine 
receptor CXCR3 which is associated with improved intratumoral infiltration of 
NK cells and reduced tumor growth of CXCL10-positive tumors in a murine 
model of melanoma (367). Additionally, transduction of NK cells to express the 
chemokine receptors CXCR2 is proposed as a strategy to improve homing of NK 
cells to tumors and thus the efficacy of NK cell ACT (368).   
ENGINEERED T CELLS 
Attempts are being made to broaden the use of ACT by engineering T cells, which 
could result in a “off-the-shelf” in vivo allogenic product accessible for a larger 
proportion of patients. Two main types of engineered T cells are currently 
available and referred to as TCR-engineered T cells and chimeric antigen receptor 
(CAR) T cells. The TCR-engineered T cells are modified to express a TCR 
recognizing an HLA tumor-derived peptide complex. The TCR-engineered T 
cells would thus be accessible for any patient harboring tumor cells that present 
the cognate HLA and target antigen. The use of TCR-engineered T cells has so 
far been limited, mostly due to significant off target effects with destruction of 
healthy tissues also expressing the tumor-associated antigen (369). The 
identification of more selective tumor antigens, unique for the tumor tissues, is 
hence desirable. An additional challenge for TCR-engineered T cell therapy is that 
it requires tumor cells to carry a functional antigen processing machinery and that 
antigens are presented on MHC. Hence, the commonly observed downregulation 
and impairment of MHC presentation, whereby the malignant cells circumvent 
CD8+ T cell immunity, will negatively influence on the anti-tumor efficacy of this 
therapy. 
 
The second type of engineered T cells, CAR T cells, do not require MHC 
presentation by the target cells as they carry an Ig variable domain from an 
antibody fused to the constant domain of a TCR (370). A CAR T cell thus 
encompasses an antibody that may recognizes any extracellular structure 
expressed by a cell, independently of MHC presentation, as well as the cytotoxic 
features of a CD8+ T cell. A limitation in CAR T cell therapy is however that only 
extracellularly expressed antigens can be detected. CAR T cells have hitherto 
mainly been developed for the recognition of CD19 on malignant B cells (in 
particular in B cell acute lymphoblastic leukemia) with initial CR rates ranging 
from 70 to 90 % in clinical trials (371). A major challenge to increase the efficacy 
of CAR T cell therapy is to improve the infiltration and survival of the infused 
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cells in solid tumors and, also, to develop strategies that take the phenotypic 
diversity of cancer cells into account.  
ANTIBODIES IN CANCER IMMUNOTHERAPY  
Monoclonal antibodies are commonly used in cancer therapy. They may be 
designed to i) inhibit signaling molecules of relevance to tumor expansion such as 
anti-VEGF antibodies, ii) neutralize checkpoint inhibition such as anti-PD-1 
antibodies, iii) induce ADCC by binding to cell surface markers expressed by the 
malignant cells such as CD19, and iv) to kill tumor cells directly or via 
complement dependent lysis. The inability of monoclonal antibodies to aid an 
immune response involving cytotoxic T cells has inspired the development of 
engineered antibodies with multiple antigen specificities, referred to as bispecific 
antibodies (BsAbs) (372). BsAbs most often consist of two or three Fab 
fragments linked together to form a construct that can recognize structures on 
different cells and hence provides a bridge between diverse cell types. BsAbs are 
either IgG-like with an intact Fc domain or non-IgG-like that lack the Fc region. 
IgG-like constructs resemble conventional antibodies in structure and have a 
longer serum half-life due to the intact FcRn region that mediates recycling of 
antibodies by reducing lysosomal degradation in endothelial cells. The non-IgG-
like constructs typically only consist of divergent Fab fragments linked to each 
other resulting in smaller molecules with better tissue penetration but with 
reduced serum half-life, partly due to a non-intact FcRn region (373). 
  
Several types of BsAbs have been generated where the bispecific T cell engagers 
(BiTEs), bispecific killer cell engagers (BiKEs), and the trispecific antibodies 
(TrAbs) are the most studied. The most common design of BiTEs and BiKEs is 
one Fab fragment recognizing CD3 on T cells or CD16 on NK cells fused with 
another Fab fragment recognizing a structure expressed by the malignant cells. 
Thereby, BiTEs and BiKEs induce T cell- or NK cell-mediated cytotoxicity 
against the cell that the BsAb attaches to. 
 
Two BsAbs, catumaxomab and blinatumomab, are approved for use in cancer 
therapy. Catumaxomab links three cell types: one Fab fragment of the antibody 
binds to EpCAM expressed by epithelial malignant cells and the other Fab 
fragment to CD3 on T cells. The third arm is an Fc domain potentially linking Fc 
receptor-expressing cells with cytotoxic function, such as NK cells or 
macrophages, to the tumor cells. Treatment with catumaxomab thus aims at 
inducing T cell cytotoxicity, phagocytosis, and ADCC against tumor cells (374) 
and is currently used in EpCAM+ cancers such as gastric, ovarian, and breast 
cancer (375, 376). The second approved BsAb, blinatumomab, is a BiTE with two 
Fab fragments recognizing CD3 and CD19, respectively, and is hence a non-IgG-
like-BsAb. Blinatumuab is approved in the treatment of B cell precursor acute 
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lymphoblastic leukemia (377). Numerous BsAbs are currently being evaluated in 
solid and hematopoietic malignancies.  
CHECKPOINT INHIBITORS 
Checkpoint inhibitors are antibodies designed to reduce T cell suppression via the 
PD-1, the CTLA-4, or related inhibitory pathways. The currently available 
antibodies targeting the PD-1- or the CTLA-4-pathways are approved in several 
forms of cancer. Expression of CTLA-4 is induced on conventional T cells 
following their activation. It binds to CD80 and CD86 on APCs with a higher 
affinity than the stimulatory receptor CD28 and transmits inhibitory signals to the 
T cell to prevent excessive activation. In addition, CTLA-4 is constitutively 
expressed by regulatory T cells, where it contributes to its immunosuppressive 
functions, possibly by capturing and removing costimulatory CD80 and CD86 
from the surface of APCs (116, 378). The rationale of using anti-CTLA-4 
antibodies is thus to enhance activation of anti-tumor T cells that may contribute 
in tumor eradication. The first anti-CTLA-4 antibody, ipilimumab, has been 
shown to induce tumor regression and improve overall survival in patients with 
metastatic melanoma (338). The clinical use of ipilimumab may, however, be 
associated with adverse immune related side-effects likely explained by enhanced 
T cell activation with ensuing autoimmunity.  
 
Whereas anti-CTLA-4 therapy enhances T cell activation during priming, 
blockade of the PD-1 pathway is assumed to foremost restore functions of 
memory T cell populations. PD-1 is expressed by activated T cells and its ligands, 
PD-L1 or PD-L2, are expressed by target cells such as malignant cells but may 
also be expressed by cells in the TME such as MDSCs and other myeloid cells. 
Under normal conditions the PD-1-pathway serves to dampen ongoing effector 
immune responses to restore homeostasis. The expression of PD-L1/L2 in the 
TME does however dampen anti-tumor immunity (369) and tumor cells are 
assumed to highjack this pathway since increased PD-L1/L2 expression renders 
effector T cells inactive. The first trials showing clinical efficacy of PD-1 blockade 
were performed in metastatic melanoma, where approximately 30 % of patients 
experienced durable tumor regression and markedly prolonged survival (339). 
Antibodies neutralizing the PD-1-pathway are currently approved for use in 
patients with melanoma, non-small cell lung cancer, lymphoma, renal cell 
carcinoma, and urothelial cancer (369). Patients receiving anti-PD-1 therapy are 
less prone to develop autoimmunity than those receiving anti-CTLA-4, possibly 
because the targeting of PD-1 preferentially restores functions of previously 
activated T cells.  
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CANCER VACCINES 
Several approaches to develop cancer vaccines have been explored including non-
targeted peptides or proteins, antigens coupled to anti-DC-antibodies, and 
infusion of ex vivo loaded DCs. Non-targeted vaccines are typically synthetic 
peptides that may be infused in combination with adjuvants to achieve optimal 
DC activation (379). Several vaccines have been shown to increase the number of 
peptide-specific T cells but the impact on the clinical course of cancer has been 
modest (380-382). The lack of clinical efficacy despite T cell activation has been 
suggested to be explained by CD4+ T cell responses skewed to secrete type II 
cytokines rather than type I cytokines such as IFN-J (382). Combining peptide 
vaccines with IFN-J has been shown to optimize T cell polarization with 
significantly more IFN-J producing antigen-specific T cells (383). Additionally, 
recent technical development has resulted in personalized cancer vaccines where 
the peptides correspond to patient-specific neoantigens (379). In addition, 
substances limiting the attraction of Tregs may be added to hinder 
immunosuppression (384). Another approach where GM-CSF is used to boost 
DC activation is the cancer cell-based vaccine GVAX where irradiated tumor cells 
are modified to express GM-CSF aiming to enhance DC recruitment and 
activation (385). In vivo targeting of DCs can also be achieved by the conjugation 
of antibodies directed against DC surface molecules to the tumor antigens (386-
388). Several adjuvants are additionally evaluated aiming at reducing activation of 
Tregs and to achieve a more robust induction of anti-tumor T cells (388, 389). 
 
An additional DC vaccine approach is the ex vivo generation and loading of DCs 
which are later infused to the patient. Sipuleucel-T is such a cellular product 
approved by the US Food and Drug Administration used for the treatment of 
metastatic prostate cancer. The treatment involves culturing antigen-presenting 
cells in the presence of a fusion protein composed of a neoantigen and GM-CSF 
and has been shown to prolong the survival of prostate cancer patients with four 
months (390). Patient-derived AML cells have also been fused with autologous 
DCs creating a broad range of neoantigens in the context of DC-derived MHC 
presentation. AML patients in CR were infused with the vaccine to target residual 
leukemic cells. The approach resulted in induced expansion of leukemic-specific 
T cells and entailed long CR duration in a smaller study (391). 
 
Several single agent cancer vaccines boost immune rejection of tumor cells but 
fail to demonstrate pro-longed efficacy in late-stage clinical studies. Thus, 
combinations of different immunotherapies, including those targeting 
immunosuppression, may be necessary for durable responses to cancer vaccines.   
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TARGETING MDSCS  
Various strategies have been explored to target MDSCs pharmacologically. 
Cancer chemotherapies such as gemcitabine and 5-flurouacil reportedly result in 
a reduction of MDSCs in murine cancer models, which may contribute to its 
therapeutic effects (392, 393). The prostaglandin E2 and cyclooxygenase-2 (COX-
2) pathway have been suggested important for the induction of MDSCs (394, 
395). Thus, inhibition of the expansion of MDSCs has been explored via targeting 
COX-2 (394, 396, 397). Additionally, the inhibition of the CSF-1 receptor, that 
growth factors driving myelopoiesis act via, have further been explored in an 
attempt to prevent the expansion of MDSCs. The infiltration of CSF-1R positive 
myeloid cells reportedly predicts poor survival in patients with neuroblastoma and 
the addition of a CSF-1R antagonist dampens tumor cell-induced generation of 
human MDSCs in vitro and reduces the formation of neuroblastoma tumors in a 
transgenic mouse model. Additionally, combining CSF-1R blockade with PD-
1/PD-L1 checkpoint inhibition enabled superior tumor control over 
monotherapy with either treatment (398).  
 
Approaches to stimulate MDSC differentiation into less suppressive myeloid cells 
include stimulation with ATRA and NOX2 inhibition (242-248) and are in 
agreement with the results from paper II. The effect of ATRA has been assessed 
in renal cell carcinoma and non-small cell lung cancer and was found to 
dramatically reduce MDSC numbers and improve the effects of immunotherapies 
using IL-2 and DC vaccines against p53 (247, 399). The efficacy of the 
combination of ATRA and ipilimumab is currently evaluated in stage IV 
melanoma (ClinicalTrials.gov identifier: NCT02403778). 
 
Targeting the immunosuppressive mechanisms utilized by MDSCs is another 
explored therapeutic strategy. A phosphodiesterase-5 inhibitor, tadalafil, 
reportedly targeted MDSCs and restored T cell function in a phase II clinical trial 
in patients with head and neck squamous cell carcinoma (400). Tadalafil was 
further tested as palliative treatment in metastatic melanoma with promising 
results. The treatment reduced the formation of NO by MDSCs in the majority 
of responding patients whereas no such effect was observed in patients 
progressing on tadalafil (401). Production of NO, ROS, and peroxynitrate results 
in nitration of the TCR and is one of the most potent immunosuppressive features 
of MDSCs. Drugs like nitroasparins that reduce oxidation is hence a promising 
approach to limit MDSC-mediated T cell suppression. Oral administration of a 
nitroasparin, NCX 4016, to tumor-bearing mice has been shown to reduce 
immunosuppression without affecting the numbers of suppressive myeloid cells 
thus suggesting the NCX 4016 influences on events downstream of myeloid cell 
activation. In further analysis NCX 4016 was found to reduce the enzyme activity 
of arginase 1 and iNOS in CD11b+ splenocytes from tumor-bearing mice to levels 
comparable with the same cell fraction isolated from tumor-free hosts (402).       
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AIMS 
The overall aim of this thesis work was to further define the role of NOX2-
derived ROS for myeloid cell function and differentiation in cancer. The specific 
aims for each paper are listed below. 
 
Paper I aimed to define the effect of NOX2-inhibition, using HDC, on the 
development of monocyte-derived DC in vitro and to study the impact of this 
mechanism on solid tumor growth in vivo.  
 
Paper II aimed to clarify how NOX2 inhibition, using HDC, affected MDSCs in 
vitro and in vivo. 
 
Paper III aimed to determine effects of NOX2 inhibition on differentiation of 
AML cells in vitro and in vivo.  
 
Paper IV aimed at assessing the importance of NOX2-derive ROS for the 
initiation and progression of CML in vivo. 
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MATERIALS AND METHODS 
ANIMAL MODELS 
The animal experiments performed in this study were approved by the Research 
Animal Ethics Committee in Gothenburg. Mice were maintained under 
pathogen-free conditions with unlimited supply of food and water according to 
the guidelines issued by the University of Gothenburg. The studies have been 
conducted in the following strains of mice: C57BL/6J, B6.129S6-Cybbtm1Dim 
lacking the gp91phox subunit of NOX2 (Nox2-deficient) and are thus incapable of 
NOX2-derived ROS formation, BALB/c, NOD.Cg-Prkdcscid 
Il2rgtm1Sug/JicTac (NOG) deficient of NK and T cells, and Rag2/OT-1 with T 
cells specific for the peptide SIINFEKL.  
SOLID TUMOR MODELS 
This thesis confers studies examining the role of NOX2-derived ROS for the in 
vivo tumor growth of murine EL-4 lymphoma, 4T1 mammary carcinoma, and 
MC-38 colon adenocarcinoma (presented in paper I and paper II). These tumor 
cell lines were chosen since they are known to induce a pronounced expansion of 
MDSCs in tumors and in the periphery. The EL-4 cell line was originally 
established by the induction of lymphoma in a C57BL/6N mouse by treatment 
with the mutagen 9,10-dimethly-1,2-benzanthracene. The EL-4 cells line is one 
of the most commonly used cell lines for studies of MDSCs during tumor growth 
in mice. The 4T1 tumor cells were originally isolated from a mammary tumor that 
was spontaneous arising in BALB/cfC3H mice. The MC-38 cells originate from 
a chemically induced grade II colon cancer in a female C57BL/6 mouse. 
 
Solid EL-4, 4T1, and MC-38 tumors were established in Nox2-competent (wild 
type, WT) or Nox2-deficient (Nox2 knockout, KO) mice by subcutaneous 
injections of tumor cells. Mice were treated with 1000-1500µg HDC three times 
weekly starting one day before tumor cell inoculation and/or 100-240µg anti-PD-
1/anti-PD-L1 antibodies three, six, and ten days post tumor cell injection. 
Tumors were measured three times per week and mice were scarified once tumors 
of untreated controls reached a median size of 1.5cm in diameter. The set-up of 
the solid tumor models is depicted in Figure 7. 
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Figure 7. Experimental set-up of solid tumor models. Mice received intraperitoneal injections 
of 1000-1500µg HDC thrice weekly starting one day before tumor cell inoculation. Three, six, and 
ten days post tumor cell inoculation mice received intraperitoneal injections of 100-240µg anti-PD-
1 (D-PD1) and anti-PD-L1 (D-PDL1). Mice were euthanized once tumors of control mice reached 
a median size of 1.5cm in diameter. Single cell suspensions from spleens and tumors were analyzed 
for ROS production, content of myeloid and lymphoid cell populations, and immunosuppressive 
features. 
AML MODEL 
In paper III the human AML cell line PLB-985 was used to study the effect of 
NOX2 inhibition on AML cell differentiation. The PLB-985 cell line was isolated 
from a 38-year-old woman in 1985 with myelomonocytic AML. By in vitro 
manipulation, a NOX2 knockout clone of the PLB-985 cells has been generated 
(403). Experiments utilizing WT and NOX2 KO PLB-985 cells allows for 
identification of the NOX2 specific targeting mechanisms of HDC. To determine 
in vivo effects of HDC on leukemic cells capable (NOX2 WT) and incapable 
(NOX2 KO) of NOX2-derived ROS-formation, 2 x 106 cells were transplanted 
to sublethally irradiated immunodeficient NOG mice by intravenous injections. 
Starting two weeks post transplantation, mice received 1500µg HDC thrice 
weekly administrated via intraperitoneal injections. Mice were euthanized once 
presenting with disease symptoms. Figure 8 shows the experimental design of this 
study.  
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Figure 8. AML disease model. Sublethally irradiated NOG mice were transplanted with WT or 
NOX2 KO PLB-985 cells. Two weeks post-transplantation, mice received intraperitoneal injections 
of 1500µg HDC thrice weekly. Mice were euthanized once showing disease symptoms. The 
frequency of human cells in BM of diseased mice was examined using flow cytometry. 
 
The AML cell line OCI-AML3 was also utilized in paper III. This cell line was 
established from the blood of a 57-year old man diagnosed with M4 AML in the 
1980s. The OCI-AML3 cells carry one of the most frequently occurring genetic 
alterations observed in AML, i.e. mutated nucleophosmin. These cells are thus 
commonly used to study the characteristics of AML carrying nucleophosmin 
mutations. 
BCR-ABL1 MODEL 
In paper IV the importance of a functional NOX2 was examined for the ability 
of BCR-ABL1+ cells to initiate a CML-like disease in an in vivo model. Murine 
BCR-ABL1+ cells were generated by transduction of 5-flurouacil-treated BM cells 
isolated from female C57BL/6J WT or Nox2 KO mice. Transduced cells were 
expanded and BCR-ABL1+ cells (reflected by the reporter protein green 
fluorescence protein) were isolated using flow cytometry. The following day, 1 x 
105 BCR-ABL1+ WT or Nox2 KO cells were transplanted to lethally irradiated 
female WT C57BL/6J mice together with 2 x 106 rescue BM cells. Disease 
initiation and progression was monitored by contentious blood draws and mice 
were euthanized upon disease symptoms or when presenting with elevated white 
blood cell counts. The in vivo CML model is depicted in Figure 9. 
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Figure 9. CML disease model. Lethally irradiated mice were transplanted with 100 000 WT or 
Nox2 KO BCR-ABL1+ cells together with 2 million rescue BM cells. Blood was collected every 
other week and analyzed for the presence of BCR-ABL1+ cells, reflected by positivity for green 
fluorescence protein, by flow cytometry. Mice were sacrificed when showing signs of disease upon 
which single cell suspensions from liver, spleen, blood, and BM were analyzed for ROS production 
and leukemic cell frequency. 
RE:MISSION TRAIL 
In paper II and paper III samples from patients receiving remission 
maintenance therapy with HDC and IL-2 were studied. The samples were 
obtained from a phase IV trial (Re:Mission trial, NCT01347996) which enrolled 
84 AML patients in first CR from 20 centers in Europe. The trial was approved 
by the Regional ethical review board in Gothenburg and all procedures of this 
study were performed in accordance with the 1964 Declaration of Helsinki and 
its later amendments or comparable ethical standards. Informed consent was 
obtained from all individual participants before enrollment. 
 
Patients received ten three-week cycles of HDC/IL-2 with three to six weeks of 
resting period in between cycles. The treatments included 0.5mg histamine and 
1µg/kg body weight IL-2 administrated by the patients themselves at home by 
subcutaneously injections twice daily. Blood was collected before and after cycle 
one and three and shipped to the Tumor Immunology lab at the Sahlgrenska 
Cancer Center that served as the central laboratory for immunological 
assessments. Patients were followed for at least two years for leukemia-free and 
overall survival (Figure 10). 
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Figure 10. Design of Re:Mission trial. AML patients in CR were enrolled after the completion 
of chemotherapy. Patients received ten three-week cycles of HDC/IL-2 therapy and blood was 
collected at the beginning and end of cycle one and three. 
STATISTICS 
STUDENT´S T-TEST 
Two-tailed student´s t-test was used to determine if the means of two data sets 
were significantly different. The test requires that each data set is normally 
distributed. The Wilcoxon matched-pairs signed rank test was used for paired 
analyses. 
ANALYSIS OF VARIANCE 
Analysis of variance (ANOVA) was employed to determine if the means of more 
than two groups differed significantly. When more than two comparisons were 
made the risk of false positive significances increases, which the ANOVA takes 
into account. We have used one-way ANOVA to compare the means between 
more than two groups and two-way ANOVA to determine how a response is 
affected by two factors such as time and treatment. 
 
For multiple comparisons Bonferroni, Holm-Sidak, and Tukey´s methods were 
used. The Bonferroni or Holm-Sidak methods compare the difference between 
selected means whereas Tukey´s method compares the means of each group with 
the mean of every other group.   
LOGRANK TEST 
The logrank test was employed to compare differences in survival distribution 
between two groups. It is a nonparametric test that does not require a normal 
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distribution. The test is constructed by adding the observed and expected number 
of events at each time point for each of the study groups. 
ADDITIONAL TECHNIQUES 
For a detailed description of standard techniques, such as flow cytometry, ROS 
measurement, and cell culturing, the reader is referred to the materials and 
methods section of the respective papers. 
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RESULTS 
PAPER I 
In paper I we aimed to study the effect of NOX2 inhibition, using HDC, on 
monocyte differentiation to DCs. Impaired generation of sufficient numbers of 
functional DCs is a commonly observed event in cancer (266, 267). Since DCs 
are essential for proper activation and propagation of T cells, including anti-tumor 
T cells, promoting the generation and function of DCs may result in improved 
anti-tumor immunity. The initial experiments in paper I assessed if HDC may 
synergize with GM-CSF and IL-4 in promoting the maturation of DCs from 
human monocytes. We observed that the addition of HDC to cell cultures 
resulted in more elongated cells, which is characteristic for DCs. Using FACS we 
demonstrated that DCs generated in the presence of HDC expressed increased 
levels of HLA-DR (Figure 11a) and the costimulatory molecules CD86 (Figure 
11b) along with CD40 and thus displayed a phenotype associated with 
professional APCs. 
 
We next examined if the activated phenotype of HDC-generated DCs resulted in 
improved functionality. Compared with control DCs, HDC-generated DCs were 
significantly better at activating CD4+ T and CD8+ T cells, as determined by 
enhanced proliferation and production of IFN-J and IL-4. To assess if the HDC-
induced expression of CD86 contributed to the observed induction of DCs, 
CD86 neutralizing antibodies were added to the cultures. This resulted in a 
significant reduction of T cell proliferation suggesting that the HDC-mediated 
induction of CD86 on DCs contributed to the improved functionality. 
 
HDC reduces NOX2-derived ROS production in human myeloid cells (38). In a 
next series of experiments, we aimed to assess if this mechanism may explain the 
pro-differentiating properties of HDC on myeloid cells. Human DCs generated 
in the presence of HDC contained reduced levels of intracellular ROS, as 
determined by DCFDA staining. The extracellular ROS scavenger catalase did 
not mimic the effect of HDC on DC maturation. To further define the role of 
NOX2-derived ROS for HDC-induced myeloid maturation, we utilized WT and 
NOX2 KO variants of the human myelomonocytic PLB-985 cell line and 
observed that only the NOX2-sufficient PLB-985 cells responded to HDC 
therapy by differentiation (Figure 11c). We thus concluded that the pro-
differentiating effect of HDC was reliant on the expression of functional NOX2. 
We also observed that the pro-differentiating effects of HDC were mediated by 
H2R signaling, since HDC did not promote differentiation of DCs or PLB-985 
WT cells in the presence of the H2R antagonist ranitidine (Figure 11c). 
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To explore if a similar pro-differentiating effect of HDC occurred in vivo, naïve 
mice were treated with HDC followed by analysis of DCs in spleen and in the 
peritoneal cavity. In vivo treatment with HDC did not impact on the number of 
DCs, nor their expression of MHC class II or CD86 in this setting. We 
hypothesized that the pro-differentiating effects of HDC might be more 
pronounced in an environment with a higher redox state, such as in the TME. We 
therefore treated EL-4 tumor-bearing mice with HDC and observed a significant 
increment in the number of intratumoral DCs (Figure 11d) along with a reduced 
tumor growth rate. A positive correlation between the number of intratumoral 
DCs and CD8+ T cells also supported that DCs favor anti-tumor immune 
responses. To determine if the in vivo effect of HDC was dependent on myeloid 
cells expressing functional NOX2, we repeated these experiments in Nox2 KO 
mice. In this setting, where the myeloid cells were unable to generate NOX2-
derived ROS, HDC did not enhance DC infiltration into tumors (Figure 11e) and 
did not reduce tumor growth in vivo. 
 
In conclusion, the results of paper I imply i) that HDC stimulates DC maturation 
by inhibiting NOX2-derived ROS formation and ii) that HDC controls growth 
of EL-4 tumors in a NOX2-dependent manner. 
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Figure 11. Results paper I. (a-b) Expression of (a) HLA-DR and (b) CD86 on monocytes (MO) 
and monocyte-derived DCs (DC) cultured in the absence (Ctrl) or presence of HDC (his). (c) 
Expression of CD11b on WT and NOX2 KO PLB-985-cells in the absence (Ctrl) or presence of 
HDC (his) and ranitidine (rani). (d-e) Frequency of CD11c+IaIe+ DCs in spleen and tumor of EL-
4 tumor-bearing (d) WT and (e) Nox2 KO mice. **p<0.01, ***p<0.001. 
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PAPER II 
Paper II aimed to further elaborate the findings from paper I of the pro-
differentiating effects of HDC on myeloid cells, with specific focus on MDSCs. 
In cancer, MDSCs show compromised differentiation and produce excessive 
amounts of ROS, which may impair anti-tumor immunity. We hypothesized that 
HDC might reverse these features of MDSCs. In a first series of experiments we 
confirmed and extended the in vivo findings from paper I showing that HDC-
treatment of EL-4 tumor-bearing mice resulted in reduced tumor growth in 
Nox2-sufficient but not in Nox2-deficient mice (Figure 12a-b). We also showed 
that HDC weakly but significantly reduced the in vivo growth of 4T1 mammary 
carcinoma with a similar trend observed in MC-38 colon carcinoma. The 
depletion of MDSCs using GR1-neutralizing antibodies abrogated the anti-tumor 
efficacy of HDC suggesting that HDC may act by targeting GR1-expressing 
MDSCs. 
 
Further analyses of the tumor-bearing mice revealed that in vivo treatment with 
HDC resulted in reduced accumulation of MDSCs in EL-4 tumors and a less 
pronounced expansion of splenocytes (which were dominated by MDSCs) in 4T1 
tumor-bearing mice. The frequency of intratumoral MDSCs in EL-4 tumor-
bearing mice and the number of splenocytes in 4T1 tumor-bearing mice 
correlated positively with tumor progression in control mice. We did not observe 
such correlations in HDC-treated mice, suggesting that the myeloid cells of 
treated mice may be less immunosuppressive and thus less prone to influence 
tumor growth. We thus examined if leukocytes from tumors and spleens of HDC-
treated EL-4 and 4T1 tumor-bearing mice showed reduced ROS-forming 
capacity. Treatment with HDC in vivo resulted in reduced ROS formation from 
myeloid cells of tumor-bearing mice ex vivo. Furthermore, spleen GR1+ cells of 
HDC-treated EL-4-bearing mice were less suppressive towards CD8+ T cells 
compared with MDSCs isolated from control EL-4 bearing mice (Figure 12c). In 
line with these results, a higher fraction of tumor-infiltrating T cells showed an 
effector phenotype in HDC-treated mice suggesting that the treatment resulted 
in a less immunosuppressive TME, favoring T cell effector responses. 
 
Effects of HDC on MDSC generation were also assessed in human monocytic 
cultures. Human monocytes were incubated in medium supplemented with IL-6 
and GM-CSF, which resulted in the generation of cells with a MDSC-like 
phenotype characterized by increased ROS formation and reduced expression of 
HLA-DR. In line with the results in mice, the addition of HDC to these cultures 
limited the generation of MDSC-like cells. We also examined the effect of HDC 
therapy on human CD14+HLA-DRlow MDSCs (M-MDSCs) in a phase IV clinical 
trial in AML where patients received cycles of HDC/IL-2 treatment. We found 
that treatment with HDC/IL-2 significantly reduced the frequency and numbers 
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of M-MDSCs (Figure 12d) and that patients with an above median reduction of 
M-MDSC numbers during the first cycles showed improved leukemia-free 
survival (Figure 12e). 
 
Our results implying that HDC targets MDSCs, both by inducing their maturation 
and by limiting their immunosuppressive functions, incited us to investigate if 
HDC may improve the response of tumor-bearing mice to PD-1/PD-L1 
blockade in vivo. We thus combined HDC treatment with antibodies against PD-
1 and PD-L1 and observed that the combined therapy was superior in reducing 
tumor growth compared with monotherapy with either HDC or PD-1/PD-L1 
checkpoint inhibition alone in EL-4 and MC-38 tumor-bearing mice (Figure 12f). 
 
Paper II thus extended the findings reported in paper I to show that HDC-
treatment i) results in reduced accumulation of MDSCs with less 
immunosuppressive features, ii) enhances the effector phenotype feature of 
tumor infiltrating CD8+ T cells, and iii) improved the anti-tumor efficacy of 
checkpoint inhibition. 
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Figure 12. Results paper II. (a-b) EL-4 tumor growth in WT (a) and Nox2 KO (b) mice. 
Untreated (solid line), HDC-treated (dashed line). (c) Percentage of proliferating CD8+ T cells in 
the absence of stimuli (n=3), in response to a control peptide (gp100, n=3) or in response to the 
OT-1 specific peptide (SIINFEKL, n=3). In specified wells, GR1+ cells that had been isolated from 
control (n=5) or HDC-treated (n=6) EL-4-bearing mice or GR1+ cells isolated from tumor-free 
mice (n=2) were present at a 1:1 ratio with the SIINFEKL stimulated OT-1 splenocytes during the 
course of proliferation. (d) Frequency of M-MDSCs before (cycle 1, day 1; C1D1) and after the first 
treatment cycle (cycle 1, day 21; C1D21) and at the beginning (cycle 3, day 1; C3D1) and end (cycle 
3, day 21; C3D21) of the third treatment cycle. (e) Impact of M-MDSC reduction on leukemia free-
survival (LFS) in patients undergoing HDC/IL-2 therapy. Patients were dichotomized by the 
median reduction of M-MDSC counts during the first treatment cycle (n=24 for each group). (g) 
MC-38 tumor growth in control (solid line), anti-PD-1/anti-PD-L1-treated (dotted line), and 
HDC/anti-PD-1/anti-PD-L1-treated (dashed line) mice. *p<0.05, **p<0.01, ***p<0.001. 
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PAPER III 
The aim of paper III was to test if HDC, in addition to inducing differentiation 
of DCs and MDSCs, may also promotes differentiation of AML blasts that 
express NOX2 and H2R. Previous studies have shown that AML cells of the 
FAB-classes M4 (myelomonocytic) and M5 (monocytic) frequently express both 
NOX2 and H2R (39), which was confirmed in this study. 
 
The addition of HDC to the NOX2- and H2R-positive myelomonocytic AML 
cell lines, PLB-985 and OCI-AML3, triggered increased expression of the myeloid 
maturation markers CD11b (Figure 13a), CD14, formyl peptide receptor 1 and 2 
(FPR1 and FPR2). HDC did however not alter differentiation of NOX2 KO 
PLB-985 cells (Figure 13a) while DMSO, a non-specific inducer of maturation, 
was equally efficacious in promoting maturation of NOX2 WT and KO cells 
(Figure 13b). In agreement, treatment of primary human AML cells expressing 
NOX2 and H2R (i.e. FAB-M4/M5 AML cells) with HDC increased the 
expression of HLA-DR (Figure 13c), FPR1, and FPR2. No such upregulation was 
observed in AML cells lacking the expression of NOX2 and H2R (i.e. FAB-
M0/M1/M2 AML cells) (Figure 13c). 
 
The only known biological role of NOX2 is to generate ROS. As expected, only 
WT, but not NOX2 KO PLB-985 cells, produced ROS in response to the NOX2-
stimulus fMLF. HDC inhibited the ROS production from WT PLB-985 cells. 
Further analysis showed that NOX2 KO cells also contained significantly less 
cytoplasmic ROS and produced lower levels of mitochondrial ROS (Figure 13d). 
These data suggest that not only are NOX2-derived ROS reduced in NOX2 KO 
cells, but there is an interplay, or feed-forward mechanism, between different 
sources of ROS. To further illuminate the role of ROS for myeloid differentiation 
WT and NOX2 KO PLB-985 cells were treated with the ROS scavengers luminol 
(that scavenges intra- and extracellular ROS) or isoluminol (that only scavenges 
extracellular ROS). Luminol triggered a pronounced differentiation of both WT 
and NOX2 KO PLB-985 cells, while the effect was modest for isoluminol (Figure 
13e). These results indicate that intracellular ROS in leukemic cells impede 
myeloid maturation and that other sources of ROS, in addition to NOX2, 
contribute to the effect. 
 
To determine NOX2-dependent down-stream effects of HDC on AML cells, WT 
and NOX2 KO PLB-985 cells were treated with HDC for two days and then 
subjected to microarray analysis. We found that a fraction of genes was regulated 
by HDC in WT cells, while virtually no genes were significantly regulated by HDC 
in NOX2 KO cells. Among genes specifically regulated by HDC in WT cells were 
genes involved in cell cycle progression. We thus performed experiments to 
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elucidate cell cycling effects of HDC and found that HDC blocked S-phase entry 
of WT but not of NOX2 KO PLB-985 cells. 
 
Effects of HDC on AML cells in vivo were further investigated in a xenograft 
model where immunodeficient NOG mice were transplanted with WT or NOX2 
KO PLB-985 cells. HDC-treated mice transplanted with WT PLB-985 AML cells 
survived slightly longer than untreated control mice and presented with 
significantly fewer CD45+ AML cells in BM at the time of sacrifice (Figure 13f). 
In contrast, HDC treatment did not affect leukemic expansion in mice 
transplanted with NOX2 KO PLB-985 AML cells (Figure 13f). The results of 
paper III thus support that HDC exerts direct effects on NOX2+ monocytic 
leukemic cells. 
 
In summary, the results of paper III imply that i) HDC exerts pro-differentiating 
effects on monocytic AML cells, ii) reduces leukemic expansion in vivo by targeting 
NOX2, and iii) HDC-mediated reduction of intracellular ROS facilitates the 
maturation of monocytic leukemic cells. 
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Figure 13. Results paper III. (a-b) Expression of CD11b+ on WT and NOX2 KO PLB-985 cells 
after (a) HDC exposure or (b) DMSO exposure. (c) Expression of HLA-DR of monocytic and 
non-monocytic primary AML cells after stimulation with HDC. (d) Levels of mitochondrial ROS 
in WT and NOX2 KO PLB-985 cells. (e) Frequency of CD11b+ WT and NOX2 KO PLB-985 cells 
after culture with luminol (Lum) or isoluminol (Isolum). (f) Percentage of leukemic cells at the time 
of sacrifice in control (Ctl) and HDC-treated (HDC) mice transplanted with WT or NOX2 KO 
PLB-985 cells. *p<0.05, **p<0.01, ***p<0.001. 
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PAPER IV 
CML is initiated and sustained by the BCR-ABL1 fusion gene. BCR-ABL1 
expression has been shown to result in elevated intracellular ROS levels in 
transformed cells but little is known regarding the role of NOX2-derived ROS 
for BCR-ABL1-induced leukemogenesis. The aim of paper IV was to investigate 
if NOX2-derived ROS contributed to the disease-initiating properties of BCR-
ABL1+ cells in vitro and in vivo. Colony-forming unit assay of murine BCR-ABL1+ 
Nox2 WT and KO cells revealed that Nox2 deficiency reduced the serial colony 
formation of BCR-ABL1+ cells suggesting that NOX2 impacts on the 
proliferation and differentiation of these cells (Figure 14a).  
 
In an in vivo setting, we observed that transplantation of Nox2 WT BCR-ABL1+ 
cells to irradiated mice resulted in a more aggressive leukemia. Hence, mice 
transplanted with Nox2 WT BCR-ABL1+ cells showed a more rapid increment of 
leukemic cells in blood (Figure 14b) and also had a shorted lifespan than mice 
transplanted with BCR-ABL1+ Nox2 KO cells (Figure 14c). Analysis of BM cells 
of diseased mice indicated that the BCR-ABL1+ Nox2 KO cells tended to be more 
mature, with a higher fraction of CD11b+GR1+ cells and fewer CD34+ immature 
cells.  
 
In conclusion, the results presented in paper IV suggest that i) NOX2 contributes 
to the initiation of BCR-ABL1 leukemia and ii) that further studies are warranted 
to define if NOX2-targeting therapies may be of value in BCR-ABL1+ leukemia. 
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Figure 14. Results paper IV. (a) Colony forming capacity of WT and Nox2 KO BCR-ABL1+ cells. 
(b) Frequency of BCR-ABL1+ WT and Nox2 KO BCR-ABL1+ cells in blood of transplanted mice. 
(c) Survival of mice transplanted with WT and Nox2 KO BCR-ABL1+ cells. *p<0.05. 
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DISCUSSION 
This thesis aimed at contributing to the understanding of the role of ROS in 
cancer and to shed light on the possibility of targeting NOX2 for therapeutic 
purposes. A recurring finding in my studies was that NOX2 is a negative regulator 
of the differentiation of normal and leukemic myeloid cells, which may be 
reverted by genetic or pharmacological targeting of NOX2. 
 
It has previously been shown that MDSCs from tumor-bearing, Nox2-deficient 
mice more readily differentiate into mature macrophages and DCs compared with 
WT counterparts ex vivo (232) implying that the induction of NOX2-derived ROS 
in MDSCs is a mechanism by which these cells maintain an immature phenotype. 
Furthermore, ATRA has been shown to trigger the generation of DC from 
monocytes (244) and to induce the maturation of MDSCs into DCs or 
macrophages by a mechanism involving upregulation of the antioxidant 
glutathione synthase, that in turn reduces the intracellular ROS levels in myeloid 
cells (248). A similar effect on differentiation was observed when MDSCs were 
subjected to the antioxidant NAC (248). 
 
Our results confirm and extend these previous findings by showing that the 
cytokine-induced generation of monocyte-derived DCs was favored by NOX2-
derived ROS inhibition using HDC. Similarly, HDC limited the cytokine-induced 
generation of human MDSCs in vitro. A pro-differentiating effect of HDC was 
also observed in vivo since treatment with HDC reduced the accumulation of 
intratumoral MDSCs and increased the infiltration of DCs in tumor-bearing mice. 
Furthermore, pharmacological inhibition of NOX2-derived ROS reduced tumor 
growth in vivo in several experimental models of solid cancer. 
 
We also determined effects of NOX2-inhibition on malignant NOX2-expressing 
myeloid cells and observed that HDC stimulated the maturation of H2R- and 
NOX2-expressing AML cells in vitro and in vivo and also reduced the expansion of 
leukemia. Similarly, transplantation of mice with NOX2 KO OCI-AML3 resulted 
in reduced expansion of leukemia and prolonged survival compared with WT 
counterparts in a xenograft AML model (162). We additionally investigated 
effects of genetic ablation of Nox2 on BCR-ABL1+ murine cells and found that 
Nox2-depleted cells showed reduced colony formation, which is indicative of a 
more mature phenotype of these cells. In line with these results, we observed a 
prolonged survival of mice transplanted with Nox2 KO BCR-ABL1+ cells vs. 
corresponding WT cells. These results thus suggest that pharmacological 
inhibition or genetic ablation of NOX2 impacts on the differentiation of non-
malignant and malignant myeloid cells and may thus reduce the growth of solid 
tumors as well as the expansion of NOX2-expressing leukemic cells. 
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The HDC-induced myeloid differentiation seems to rely on the ability of HDC to 
limit the generation of intracellular ROS rather than inhibiting the extracellular 
release of NOX2-derived ROS. This assumption is based on results showing that 
only scavengers of intracellular ROS mimicked the pro-differentiating effect of 
HDC. However, the addition of an intracellular scavenger of ROS to NOX2 KO 
PLB-985 cells promoted differentiation suggesting that sources of ROS other 
than NOX2 contributed to the impaired differentiation of these cells. 
Experiments using the H2R antagonist ranitidine showed that the pro-
differentiating effect of HDC was mediated by H2R. We also observed that only 
NOX2-expressing myeloid cells differentiated in response to HDC and 
additionally that HDC did not affect EL-4 tumor growth in Nox2-deficient mice 
or in mice depleted of GR1+ myeloid cells. Similarly, HDC therapy did not alter 
leukemic cell differentiation or progression in NOG mice transplanted with 
NOX2 KO monocytic PLB-985 cells. Based on these results we propose that 
HDC facilitates the differentiation of myeloid cells by ligating H2R to inhibit the 
formation of intracellular NOX2-derived ROS. This assumption is, in part, 
supported by studies showing that overexpression of H2R in the monocytic U937 
cell line or exposure of these cells to specific H2R agonists results in terminal 
differentiation (404, 405). 
 
Treatment of AML patients with HDC has been proposed to facilitate immune-
mediated clearance of leukemic cells by targeting immunosuppressive ROS (39, 
198, 202). Since MDSCs may exert NOX2-dependent, ROS-mediated 
immunosuppression we speculated that HDC, in addition to promoting the 
maturation of MDSCs, may also render these cells less immunosuppressive. We 
thus examined the ex vivo formation of ROS from leukocytes from control and 
HDC-treated mice and observed that cells isolated from HDC-treated mice 
produced significantly less ROS compared with cells from non-treated mice. The 
reduced formation of ROS translated into cells with reduced ability to suppress 
antigen-induced T cell proliferation. In line with the ex vivo results, we observed 
that HDC treatment triggered an increased frequency if CD8+ T cells with an 
effector phenotype within tumors suggesting that reduced ROS levels in the TME 
promoted anti-tumor immunity. 
 
The anti-tumor efficacy of antibodies targeting the PD-1-pathway has been 
reported to rely on pre-existing cytotoxic CD8+ T cells (406) and anti-CSF-1 
therapy, that limits the expansion of MDSCs, was previously shown to synergize 
with antibodies targeting the PD-1-pathway in reducing the growth of murine 
neuroblastoma (398). We observed that treatment of mice carrying EL-4 
lymphoma or MC-38 colon carcinoma with HDC potentiated the anti-tumor 
efficacy of checkpoint inhibitors to the PD-1 pathway. In summary, the results 
suggest that targeting of NOX2 using HDC is conceivable in cancers where 
myeloid cells, such as MDSCs, generate immunosuppressive ROS. Our findings 
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also point to the possibility of adding HDC, or other NOX2-inhibitors, in cancer 
therapy using immune checkpoint inhibitors. 
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CONCLUDING REMARKS 
Our results imply that NOX2-derived ROS exert multiple functions in different 
malignancies and that the targeting of NOX2-derived ROS may have clinical 
implications. Whereas the results in paper I and paper II support that the 
inhibition of NOX-derived ROS using HDC promotes the differentiation of 
immature immunosuppressive cells and thus stimulates the generation of DCs in 
solid tumors, the results from paper III and paper IV imply that NOX2 
inhibition may also directly target malignant myeloid cells. 
 
In the attempts to define the impact of NOX2 on tumor growth in vivo we utilized 
several murine tumor models, all of which have significant limitations. The cell 
lines used to generate solid tumors were not orthotopically implanted and may 
not appropriately reflect the course of disease in these malignancies. We opted 
for this approach as the heterotopic implantation of EL-4 lymphoma, 4T1 
mammary carcinoma, and MC-38 colon cancer cells results in a pronounced 
expansion of MDSCs. It thus remains to be established whether our results are 
relevant to the course of lymphoma, breast cancer, and colon cancer. The results 
may instead reflect the effects of NOX2 inhibition in cancer characterized by 
MDSCs expansion. In the CML model the transplantation of BCR-ABL1+ cells 
to mice resulted in vigorous myeloproliferation and a rapid onset of leukemia. 
The disease that develops in these mice hence resembles the acute phase of CML 
rather than the chronic phase of the disease. 
 
In all parts of this thesis we have utilized Nox2-deficient mice or NOX2-deficient 
human cell lines to decipher effects of HDC in the context of NOX2 inhibition. 
The overriding conclusion is that treatment with HDC does not affect tumor 
growth and does not regulate malignant cell differentiation when NOX2 is 
genetically depleted. A limitation to these models is that NOX2 KO cells and 
Nox2-deficient mice may express features unrelated to NOX2 deficiency to 
compensate for the inability to induce NOX2-derived ROS. Notably, however, a 
recent study utilized mice that were genetically deprived of any one of the five 
major NOX2 subunits. The authors observed reduced tumor growth and/or 
metastasis regardless of which NOX2 subunit that was deleted, thus reducing the 
likelihood that phenotypes unrelated to NOX2 depletion may have biased the 
interpretation of the results (236). 
 
The effects of HDC on MDSCs were also evaluated in the Re:Mission trial. This 
was a phase IV clinical trial where all patients received HDC/IL-2. We therefore 
cannot exclude that the IL-2 component of this regimen may have contributed to 
the observed effects on MDSCs. However, a study in renal cell carcinoma showed 
that combined therapy with ATRA and IL-2 reduced the number of MDSCs 
whereas monotherapy with IL-2 did not impact on MDSC numbers (247). An 
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additional reservation is that all patients included in the trial had received high 
doses of chemotherapy before inclusion. The observed effects on myeloid 
populations could hence reflect the re-establishment of normal hematopoiesis. 
 
The results from all in vitro and in vivo models however support that HDC reduces 
tumor cell growth by i) targeting immunosuppressive ROS and/or ii) by 
stimulating myeloid cell differentiation. With the above-mentioned reservations, 
NOX2 inhibition is a conceivable target for improved cancer therapy.  
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